1
|
Conca V, Germani M, Moretto R, Giordano M, Bergamo F, Prisciandaro M, Antoniotti C, Ugolini C, Santini D, Cupini S, Boccaccino A, Barsotti G, Pagani F, Niccoli C, Zaniboni A, Passardi A, Tamburini E, Latiano T, Fontanini G, Cremolini C. 341P Trop2 and Nectin4 immunohistochemical expression in metastatic colorectal cancer: An exploratory analysis of the TRIBE2 study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
2
|
Fasola G, Barducci M, Pelizzari G, Aprile G, Grossi F, Pinto C, Daniele B, Giordano M, Ortega C, Silva R, Tozzi V, Cavanna L. 1337P Implementation of precision oncology in clinical practice: A nationwide survey in Italy. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
3
|
Germani M, Rossini D, Vetere G, Giordano M, Capone I, Manca P, Bergamo F, Conca V, Borelli B, Boccaccino A, Angelini M, Simionato F, Pella N, Morelli C, Zucchelli G, Cremolini C. 367P Prospective evaluation of emergent RAS and BRAF mutations in pre-treated metastatic colorectal cancer patients candidate to anti-EGFR re-treatment: Preliminary findings from the PARERE study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
4
|
Reyes-Bravo DY, Villalobos-Aguilera P, Almonte-Zepeda JT, Mendoza-Trejo MS, Giordano M, Orozco A, Rodríguez VM. Chronic atrazine exposure increases the expression of genes associated with GABAergic and glutamatergic systems in the brain of male albino rat. Front Toxicol 2022; 4:933300. [PMID: 36071823 PMCID: PMC9441881 DOI: 10.3389/ftox.2022.933300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2022] [Accepted: 07/19/2022] [Indexed: 11/24/2022] Open
Abstract
The herbicide atrazine (ATR; 2-chloro-4-ethylamino-6-isopropylamino-s-triazine) is widely used to destroy grasses and broadleaf weeds in crops and some fruits. Studies in rodents have shown that acute, repeated or chronic exposure to ATR is associated with alterations in the nigrostriatal dopaminergic pathway, whereas its effects on GABAergic and glutamatergic pathways have only recently been reported. Sprague-Dawley male rats were exposed daily to 1 or 10 mg ATR/kg of BW for 13 months to evaluate the ATR effects on GABAergic and glutamatergic systems. At the end of the ATR treatment, the levels of mRNA of several genes involved in the production, vesiculation, reuptake, and receptors of GABA and Glu in the striatum (STR), nucleus accumbens (NAcc), prefrontal cortex (PFC), ventral midbrain (vMID) and hippocampus (HIPP) were evaluated by absolute qPCR. For the GABAergic genes, increased expression of GAD67 and Slc32a1 in STR and/or vMID in rats exposed to 1 and/or 10 mg ATR were detected. With regard to the expression of genes involved in the glutamatergic system, Slc17a6 and Grin1 in HIPP of rats exposed to 1 and/or 10 mg ATR, increased as was Gria1 in STR and PFC in the group exposed to 1 mg ATR. In the same fashion, Slc1a3 expression and MGLUR1 increased in STR of rats exposed to 1 and 10 mg ATR groups. The expression of the glutaminases gls (variants 1 and 2) was greater in STR, NAcc, HIPP, and PFC of rats exposed to 1 and/or 10 mg ATR. These findings show that the GABAergic and, especially glutamatergic systems are targets of ATR exposure.
Collapse
Affiliation(s)
- D. Y. Reyes-Bravo
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, México
| | - P. Villalobos-Aguilera
- Departamento de Neurobiología Celular y Molecular, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, México
| | - J. T. Almonte-Zepeda
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, México
| | - M. S. Mendoza-Trejo
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, México
| | - M. Giordano
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, México
| | - A. Orozco
- Departamento de Neurobiología Celular y Molecular, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, México
| | - V. M. Rodríguez
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, México
- *Correspondence: V. M. Rodríguez,
| |
Collapse
|
5
|
Boccaccino A, Borelli B, Intini R, Antista M, Bensi M, Rossini D, Passardi A, Tamberi S, Giampieri R, Antonuzzo L, Noto L, Roviello G, Zichi C, Salati M, Puccini A, Noto C, Parisi A, Rihawi K, Persano M, Crespi V, Libertini M, Giordano M, Moretto R, Lonardi S, Cremolini C. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. ESMO Open 2022; 7:100506. [PMID: 35696748 PMCID: PMC9271503 DOI: 10.1016/j.esmoop.2022.100506] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2022] [Revised: 04/03/2022] [Accepted: 04/06/2022] [Indexed: 11/15/2022] Open
Abstract
Background Encorafenib plus cetuximab with or without binimetinib showed increased objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared with chemotherapy plus anti-EGFR in previously treated patients with BRAF V600E-mutated (mut) metastatic colorectal cancer (mCRC). Although no formal comparison was planned, addition of binimetinib to encorafenib plus cetuximab did not provide significant efficacy advantage. Patients and methods This real-life study was aimed at evaluating safety, activity, and efficacy of encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mut mCRC treated at 21 Italian centers within a nominal use program launched in May 2019. Results Out of 133 patients included, 97 (73%) received encorafenib plus cetuximab (targeted doublet) and 36 (27%) the same therapy plus binimetinib (targeted triplet). Most patients had Eastern Cooperative Group Performance Status (ECOG-PS) of 0 or 1 (86%), right-sided primary tumor (69%), and synchronous disease (66%). Twenty (15%) tumors were DNA mismatch repair deficiency (dMMR)/microsatellite instability (MSI)-high. As many as 44 (34%) patients had received two or more prior lines of therapy, 122 (92%) were previously exposed to oxaliplatin, and 109 (82%) to anti-vascular endothelial growth factor (anti-VEGF). Most frequent adverse events were asthenia (62%) and anti-EGFR-related skin rash (52%). Any grade nausea (P = 0.03), vomiting (P = 0.04), and diarrhea (P = 0.07) were more frequent with the triplet therapy, while melanocytic nevi were less common (P = 0.06). Overall, ORR and disease control rate (DCR) were 23% and 69%, respectively, with numerically higher rates in the triplet group (ORR 31% versus 17%, P = 0.12; DCR 78% versus 65%, P = 0.23). Median PFS and OS were 4.5 and 7.2 months, respectively. Worse ECOG-PS, peritoneal metastases, and more than one prior treatment were independent poor prognostic factors for PFS and OS. Clonality of BRAF mutation measured as adjusted mutant allele fraction in tumor tissue was not associated with clinical outcome. Conclusions Our real-life data are consistent with those from the BEACON trial in terms of safety, activity, and efficacy. Patients in good general condition and not heavily pretreated are those more likely to derive benefit from the targeted treatment. Encorafenib plus cetuximab ± binimetinib is safe and effective for BRAF V600E mut mCRC even in the real-world setting. Median OS is slightly shorter than in the BEACON trial, probably due to less selected patients in real life. Patients deriving more benefit from targeted therapy are likely those in good general conditions and not heavily pretreated. BRAF adjusted MAF is worth further investigation to better characterize the genomic heterogeneity of BRAF V600E mut mCRC.
Collapse
Affiliation(s)
- A Boccaccino
- Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
| | - B Borelli
- Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
| | - R Intini
- Medical Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV-IRCCSP, Padova, Italy
| | - M Antista
- Medical Oncology Department, ENETS Center of Excellence, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - M Bensi
- Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; Università Cattolica del Sacro Cuore, Roma, Italy
| | - D Rossini
- Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
| | - A Passardi
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
| | - S Tamberi
- UOC Oncologia Ravenna, AUSL Romagna, Ravenna, Italy
| | - R Giampieri
- Clinica Oncologica, Dipartimento Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy
| | - L Antonuzzo
- Clinical Oncology Unit, Careggi University Hospital, Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy
| | - L Noto
- UOC Oncologia Medica, Policlinico "G.Rodolico" AOU Policlinico - San Marco, Catania, Italy
| | - G Roviello
- Department of Health Sciences, University of Florence, Florence, Italy
| | - C Zichi
- Oncologia Medica, A.O. Ordine Mauriziano - Umberto I, Torino, Italy
| | - M Salati
- Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy; PhD Program Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy
| | - A Puccini
- Università degli Studi di Genova, Ospedale Policlinico San Martino IRCCS, Genova, Italy
| | - C Noto
- Università degli Studi di Udine, Dipartimento di Area Medica, Udine, Italy; Azienda Sanitaria Universitaria Friuli Centrale, Dipartimento di Oncologia medica, Udine, Italy
| | - A Parisi
- Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy; Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy
| | - K Rihawi
- IRCSS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - M Persano
- Medical Oncology, University of Cagliari, Cagliari, Italy
| | - V Crespi
- Department of Oncology, University of Turin, Torino, Italy
| | - M Libertini
- Oncology Unit, Poliambulanza Foundation, Brescia, Italy
| | - M Giordano
- Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
| | - R Moretto
- Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
| | - S Lonardi
- Medical Oncology 3, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
| | - C Cremolini
- Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
| |
Collapse
|
6
|
Antoniotti C, Boccaccino A, Seitz R, Giordano M, Rossini D, Ambrosini M, Salvatore L, McGregor K, Bergamo F, Conca V, Leonetti S, Provenzano L, Tamberi S, Ramundo M, Tortora G, Rasola C, Ross D, Passardi A, Nielsen T, Varga M, Cremolini C. SO-36 An immune-related gene expression profile predicts the efficacy of adding atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer: A translational analysis of the phase II randomized AtezoTRIBE study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
7
|
Marzullo R, Gaio G, Giordano M, Palladino M, Ancona R, Scognamiglio G, D‘Alto M, Russo M, Sarubbi B. P156 TRANSCATHETER CLOSURE OF ATRIAL SEPTAL DEFECT IN OVER 60 YEARS OLD PATIENTS. Eur Heart J Suppl 2022. [DOI: 10.1093/eurheartj/suac012.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Background
Ostium secundum ASD (ASDII) is the most common type of congenital heart disease in adults. Percutaneous closure has emerged as the first–line treatment for the majority of ASDII. However, the occurrence of Pulmonary Hypertension (PH) with combined pre– and post–capillary component may render ASD management challenging in elderly patients.
Methods
We report the hemodynamic data and clinical findings of elderly patients (> 60 years old) undergoing transcatheter closure of an ASDII at our department.
Results
From 2000 to 2021, 82 elderly patients were scheduled (mean age 65,4+ 4,4) of which 60 (73%) were female. Systemic arterial hypertension and supraventricular arrhythmias were the most common comorbidities accounting respectively 51% and 38% of cases. The right ventricular overload supported the ASD closure in 76 cases (93%) and paradoxical embolism in the remaining 6 (7%). 17 patients (21%) were in NYHA class III– IV. At right heart catheterization, 33 patients had normal pulmonary arterial pressure and 49 patients showed a mean pulmonary artery pressure > 20 mmhg. In the latter cohort, 33 showed a pulmonary artery wedge pressure (PAWP) < 15 mmHg (Group I) and 16 > 15 mmHg (Group II). The device implantation was completed in all patients except one with elevated pulmonary vascular resistance (PVR) of the Group I. For 14 patients of Group II, balloon occlusion test was required during the catheterization. ASD closure was achieved promptly in 10 patients. However, to reduce the risk of acute pulmonary oedema, in one case we created a small fenestration in the occluder device and in other case we retained the patency of additional defect (both patients exhibiting slightly PAWP increase during balloon occlusion test). In one patient showing significantly PAWP increase during balloon test, delayed ASD closure was performed ensuring the improvement of hemodynamic parameters at 3 months initiation of medical therapy with angiotensin–converting enzyme inhibitor and loop diuretic diuretics. For the remaining 4 patients, the percutaneous closure was not been done because of prohibitive hemodynamic parameters. Overall, ASD closure was performed successfully in 94% of cases.
Conclusions
Age and comorbidities are not absolute contraindications to ASDII percutaneous closure. In the complex cases, both medical therapies and balloon occlusion test may be use to support the decision–making process.
Collapse
Affiliation(s)
- R Marzullo
- UOC CARDIOLOGIA E UTIC PEDIATRICA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI “OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOSD CARDIOPATIE CONGENITE DELL’ADULTO, UNIVERSITÀ DELLA CAMPANIA “L. VANVITELLI”, OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOC CARDIOLOGIA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI”, OSPEDALE. MONALDI– AORN OSPEDALI DEI COLLI, NAPOLI
| | - G Gaio
- UOC CARDIOLOGIA E UTIC PEDIATRICA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI “OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOSD CARDIOPATIE CONGENITE DELL’ADULTO, UNIVERSITÀ DELLA CAMPANIA “L. VANVITELLI”, OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOC CARDIOLOGIA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI”, OSPEDALE. MONALDI– AORN OSPEDALI DEI COLLI, NAPOLI
| | - M Giordano
- UOC CARDIOLOGIA E UTIC PEDIATRICA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI “OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOSD CARDIOPATIE CONGENITE DELL’ADULTO, UNIVERSITÀ DELLA CAMPANIA “L. VANVITELLI”, OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOC CARDIOLOGIA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI”, OSPEDALE. MONALDI– AORN OSPEDALI DEI COLLI, NAPOLI
| | - M Palladino
- UOC CARDIOLOGIA E UTIC PEDIATRICA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI “OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOSD CARDIOPATIE CONGENITE DELL’ADULTO, UNIVERSITÀ DELLA CAMPANIA “L. VANVITELLI”, OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOC CARDIOLOGIA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI”, OSPEDALE. MONALDI– AORN OSPEDALI DEI COLLI, NAPOLI
| | - R Ancona
- UOC CARDIOLOGIA E UTIC PEDIATRICA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI “OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOSD CARDIOPATIE CONGENITE DELL’ADULTO, UNIVERSITÀ DELLA CAMPANIA “L. VANVITELLI”, OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOC CARDIOLOGIA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI”, OSPEDALE. MONALDI– AORN OSPEDALI DEI COLLI, NAPOLI
| | - G Scognamiglio
- UOC CARDIOLOGIA E UTIC PEDIATRICA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI “OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOSD CARDIOPATIE CONGENITE DELL’ADULTO, UNIVERSITÀ DELLA CAMPANIA “L. VANVITELLI”, OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOC CARDIOLOGIA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI”, OSPEDALE. MONALDI– AORN OSPEDALI DEI COLLI, NAPOLI
| | - M D‘Alto
- UOC CARDIOLOGIA E UTIC PEDIATRICA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI “OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOSD CARDIOPATIE CONGENITE DELL’ADULTO, UNIVERSITÀ DELLA CAMPANIA “L. VANVITELLI”, OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOC CARDIOLOGIA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI”, OSPEDALE. MONALDI– AORN OSPEDALI DEI COLLI, NAPOLI
| | - M Russo
- UOC CARDIOLOGIA E UTIC PEDIATRICA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI “OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOSD CARDIOPATIE CONGENITE DELL’ADULTO, UNIVERSITÀ DELLA CAMPANIA “L. VANVITELLI”, OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOC CARDIOLOGIA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI”, OSPEDALE. MONALDI– AORN OSPEDALI DEI COLLI, NAPOLI
| | - B Sarubbi
- UOC CARDIOLOGIA E UTIC PEDIATRICA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI “OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOSD CARDIOPATIE CONGENITE DELL’ADULTO, UNIVERSITÀ DELLA CAMPANIA “L. VANVITELLI”, OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOC CARDIOLOGIA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI”, OSPEDALE. MONALDI– AORN OSPEDALI DEI COLLI, NAPOLI
| |
Collapse
|
8
|
Ancona R, Gaio G, Giordano M, Marzullo R, Cappelli Bigazzi M, Palladino M, Scognamiglio G, Sarubbi B, Russo M. C84 PERCUTANEOUS TREATMENT OF INTERATRIAL MULTIFENESTRATE ANEURYSM IN PAEDIATRIC POPULATION: INFLUENCE OF THE LAYOUT DURING MID–TERM AND LONG–TERM FOLLOW–UP. Eur Heart J Suppl 2022. [DOI: 10.1093/eurheartj/suac011.082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Background
Multifenestrate aneurysms of interatrial septum (ISA) are a challenge in paediatric age, not only for the complex anathomy, but also for small body surface and small dimensions of cardiac chambers of the patients, that may limit the use of large and multiple devices. Aim of the study: to evaluate the efficacy of percutaneous closure of multifenestrate aneurysms during mid–term and long–term follow–up; to evaluate if the morphological characteristics of interatrial septum may influence the success of the procedure.
Materials and Methods
We retrospectively analyzed 63 patients (mean–age 9,12±3,12 years) undergone to cardiac catheterism from 2000 to 2021, for percutaneous closure of interatrial aneurysm in our division of Cardiology, subdivided into 3 groups on the basis of side and morphological characteristics of the interatrial aneurysm: Group I (2 o more defects DIA>5 mm); Group II (one defect >5 mm and more than one further fenestrations); Group III (multiple fenestrations).
Results
Percutaneous closure was efficacy in 60 patients (95%), while in 3 patients (5%) surgery closure was necessary. In half of the treated patients (30) we used 2 devices. Complications occurred in 4 patients (6%). Only in 2 patients occurred major complications (Atrio–Ventricular Block that needed PMK implantation and partial displacement of device, treated by removal and percutaneous replanting). Residual shunts, not emodynamically significant appear in the immediate post–operative period in 26% and during the follow–up in 18%. The group I was associated with greater risk of failure of the procedure (P < 0.01) and need of implantations of more than one devices (P < 0.01).
Conclusions
Percutaneous closure of multifenestrate aneurysm of interatrial septum in paediatric age are effective and shows low incidence of failure and complications. If is present residual shunt is not significant. The anathomy of interatrial septum influences procedural outcome.
Collapse
Affiliation(s)
- R Ancona
- UOC CARDIOLOGIA E UTIC PEDIATRICA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI “OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOSD CARDIOPATIE CONGENITE DELL’ADULTO, UNIVERSITÀ DELLA CAMPANIA “L. VANVITELLI”,OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI
| | - G Gaio
- UOC CARDIOLOGIA E UTIC PEDIATRICA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI “OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOSD CARDIOPATIE CONGENITE DELL’ADULTO, UNIVERSITÀ DELLA CAMPANIA “L. VANVITELLI”,OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI
| | - M Giordano
- UOC CARDIOLOGIA E UTIC PEDIATRICA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI “OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOSD CARDIOPATIE CONGENITE DELL’ADULTO, UNIVERSITÀ DELLA CAMPANIA “L. VANVITELLI”,OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI
| | - R Marzullo
- UOC CARDIOLOGIA E UTIC PEDIATRICA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI “OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOSD CARDIOPATIE CONGENITE DELL’ADULTO, UNIVERSITÀ DELLA CAMPANIA “L. VANVITELLI”,OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI
| | - M Cappelli Bigazzi
- UOC CARDIOLOGIA E UTIC PEDIATRICA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI “OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOSD CARDIOPATIE CONGENITE DELL’ADULTO, UNIVERSITÀ DELLA CAMPANIA “L. VANVITELLI”,OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI
| | - M Palladino
- UOC CARDIOLOGIA E UTIC PEDIATRICA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI “OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOSD CARDIOPATIE CONGENITE DELL’ADULTO, UNIVERSITÀ DELLA CAMPANIA “L. VANVITELLI”,OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI
| | - G Scognamiglio
- UOC CARDIOLOGIA E UTIC PEDIATRICA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI “OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOSD CARDIOPATIE CONGENITE DELL’ADULTO, UNIVERSITÀ DELLA CAMPANIA “L. VANVITELLI”,OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI
| | - B Sarubbi
- UOC CARDIOLOGIA E UTIC PEDIATRICA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI “OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOSD CARDIOPATIE CONGENITE DELL’ADULTO, UNIVERSITÀ DELLA CAMPANIA “L. VANVITELLI”,OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI
| | - M Russo
- UOC CARDIOLOGIA E UTIC PEDIATRICA, UNIVERSITÀ DELLA CAMPANIA “L.VANVITELLI “OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI; UOSD CARDIOPATIE CONGENITE DELL’ADULTO, UNIVERSITÀ DELLA CAMPANIA “L. VANVITELLI”,OSPEDALE MONALDI – AORN DEI COLLI, NAPOLI
| |
Collapse
|
9
|
Procopio G, Chiuri V, Giordano M, Alitto A, Maisano R, Bordonaro R, Cinieri S, Rossetti S, De Placido S, Airoldi M, Galli L, Gasparro D, Ludovico G, Guglielmini P, Carella C, Nova P, Aglietta M, Schips L, Beccaglia P, Sciarra A, Livi L, Santini D, Procopio G, Chiuri V, Mantini G, Roberto Bordonaro RM, Cinieri S, Rossetti S, De Placido S, Airoldi M, Galli L, Gasparro D, Ludovico GM, Guglielmini PF, Santini D, Naglieri E, Fagnani D, Aglietta M, Livi L, Schips L, Passalacqua R, Fiore M, D'Angelillo RM, Ceresoli GL, Magrini S, Rondonotti D, Mirone V, Ferriero MC, Sciarra A, Acquati M, Boccardo F, Scagliotti GV, Mencoboni M, De Giorgi U, Micheletti G, Lanzetta G, Sartori D, Carlini P, Soto Parra HJ, Battaglia M, Uricchio F, Bernardo A, De Lisa A, Carrieri G, Ardizzoia A, Aieta M, Pisconti S, Marchetti P, Paiar F. Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study. ESMO Open 2022; 7:100431. [PMID: 35405438 PMCID: PMC9058899 DOI: 10.1016/j.esmoop.2022.100431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2021] [Revised: 01/14/2022] [Accepted: 02/07/2022] [Indexed: 12/24/2022] Open
Abstract
Background Limited real-world data exist on the effectiveness and safety of abiraterone acetate plus prednisone (abiraterone hereafter) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) naive to chemotherapy. Most of the few available studies had a retrospective design and included a small number of patients. In the interim analysis of the ABItude study, abiraterone showed good clinical effectiveness and safety profile in the chemotherapy-naive setting over a median follow-up of 18 months. Patients and methods We evaluated clinical and patient-reported outcomes (PROs) of chemotherapy-naive mCRPC patients treated with abiraterone as for clinical practice in the Italian, observational, prospective, multicentric ABItude study. mCRPC patients were enrolled at abiraterone start (February 2016-June 2017) and followed up for 3 years; clinical endpoints and PROs, including quality of life (QoL) and pain, were prospectively collected. Kaplan–Meier curves were estimated. Results Of the 481 patients enrolled, 454 were assessable for final study analyses. At abiraterone start, the median age was 77 years, with 58.6% elderly patients and 69% having at least one comorbidity (57.5% cardiovascular diseases). Visceral metastases were present in 8.4% of patients. Over a median follow-up of 24.8 months, median progression-free survival (any progression reported by the investigators), time to abiraterone discontinuation, and overall survival were, respectively, 17.3 months [95% confidence interval (CI) 14.1-19.4 months], 16.0 months (95% CI 13.1-18.2 months), and 37.3 months (95% CI 36.5 months-not estimable); 64.2% of patients achieved ≥50% reduction in prostate-specific antigen. QoL assessed by Functional Assessment of Cancer Therapy—Prostate, the European Quality of Life 5 Dimensions 3 Level, and European Quality of Life Visual Analog Scale remained stable during treatment. Median time to pain progression according to Brief Pain Inventory data was 31.1 months (95% CI 24.8 months-not estimable). Sixty-two patients (13.1%) had at least one adverse drug reaction (ADR) and 8 (1.7%) one serious ADR. Conclusion With longer follow-up, abiraterone therapy remains safe, well tolerated, and active in a large unselected population. A prospective real-life study of abiraterone acetate in mCRPC patients. In 481 chemotherapy-naive mCRPC patients (median follow-up: 25 months), abiraterone plus prednisone was effective and safe. QoL, measured with various tools, remained stable during treatment with abiraterone plus prednisone. The median time to pain progression was 31.1 months.
Collapse
|
10
|
Florio M, Careri S, Zoccali C, Aulisa AG, Falciglia F, Toniolo RM, Giordano M. Reconstruction of metatarsal bone after giant cell tumor resection with no vascularized fibular graft in a pediatric patient: Case report and review of literature. Front Pediatr 2022; 10:970309. [PMID: 36313876 PMCID: PMC9597191 DOI: 10.3389/fped.2022.970309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Accepted: 09/20/2022] [Indexed: 11/13/2022] Open
Abstract
The Giant Cell tumor (GCT) is a benign, locally aggressive lesion that cause bone destruction and shows a malignant potential. It is a relatively common skeletal tumor that is therefore typically seen in young adults. Few cases are described in literature of GCT in the immature skeleton, and the metatarsal is an unusual location for a primary bone GCT, especially in pediatric age. Therefore, there are very few data reported regarding the management protocol of GCT in metatarsal bones. We report a case about the use of no vascularized fibular graft for an original Y-shaped reconstruction of the metatarsal bone after Giant Cell Tumor resection in a 9 years-old patient, and performed a literature review about metatarsal bone reconstruction in skeletally immature patient.
Collapse
Affiliation(s)
- M Florio
- Department of Surgery and Transplant, Division of Traumatology, Bambino Gesu' Children Hospital (IRCCS), Rome, Italy
| | - S Careri
- Department of Surgery and Transplant, Division of Traumatology, Bambino Gesu' Children Hospital (IRCCS), Rome, Italy
| | - C Zoccali
- Department of Human Anatomy, Histology, Forensic Medicine, Orthopedics, Sapienza University, Rome, Italy
| | - A G Aulisa
- Department of Surgery and Transplant, Division of Traumatology, Bambino Gesu' Children Hospital (IRCCS), Rome, Italy.,University of Cassino and Southern Lazio, Cassino, Italy
| | - F Falciglia
- Department of Surgery and Transplant, Division of Traumatology, Bambino Gesu' Children Hospital (IRCCS), Rome, Italy
| | - R M Toniolo
- Department of Surgery and Transplant, Division of Traumatology, Bambino Gesu' Children Hospital (IRCCS), Rome, Italy
| | - M Giordano
- Department of Surgery and Transplant, Division of Traumatology, Bambino Gesu' Children Hospital (IRCCS), Rome, Italy
| |
Collapse
|
11
|
Dell'Annunziata F, Folliero V, Zannella C, Giordano M, Galiero R, Galdiero M. Comment on: Chronic intravascular coagulation in liver cirrhosis predicts a high hemorrhagic risk. Eur Rev Med Pharmacol Sci 2021; 25:7616-7618. [PMID: 34982421 DOI: 10.26355/eurrev_202112_27605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Affiliation(s)
- F Dell'Annunziata
- Department of Experimental Medicine, Section of Microbiology, University of Campania Luigi Vanvitelli, Naples, Italy.
| | | | | | | | | | | |
Collapse
|
12
|
D'Alto M, Chessa M, Santoro G, Giordano M, Gaio G, Romeo E, Argiento P, Wacker J, D'Aiello F, Sarubbi B, Russo MG, Golino P, Costantine A, Naeije R, Dimopoulos K. The adding value of fluid challenge and balloon occlusion tests in patients with atrial septal defect. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Careful, step-wise assessment is required in all patients with an atrial septal defect (ASD) to exclude pre-existing pulmonary vascular disease or left ventricular disease. Fluid challenge test (FCT) and balloon occlusion testing (BOT) may unmask left ventricular disease and challenge the pulmonary circulation, but their complementary role in the evaluation of patients with “operable” ASD is not well established.
Aim
To evaluate the haemodynamic changes of the pulmonary circulation by FCT and BOT in ASD patients undergoing percutaneous closure according to the current guidelines.
Methods
Consecutive patients selected for percutaneous ASD closure underwent invasive hemodynamic assessment at baseline and after BOT, FCT and both.
Results
Fifty patients (mean age 47.3±11.7 years, 72% female) were included. All patients had a pulmonary-to-systemic flow ratio (QP/QS) ≥1.5, pulmonary vascular resistance (PVR) <5 WU and pulmonary arterial wedge pressure (PAWP) <15 mmHg. Individuals with a PVR ≥2 WU at baseline were older, more symptomatic, with a higher baseline systemic vascular resistance compared to the lower PVR group (PVR <2 WU; p<0.0001). The response of Qp/Qs to FCT was different between groups (p<0.0001, Figure 1). Patients with a lower baseline PVR experienced an increase in Qp/Qs, which remained above 1.5 in all patients, whereas in almost all (90%) patients with a higher baseline PVR, the Qp/Qs fell to below 1.5.
FCT caused a marked increase in pulmonary blood flow of almost 2 liters (p<0.0001) accompanied by increases in PAWP (p<0.0001). BOT led to a modest increase in PAWP (Δ1.5 [−1.0–7.0] mmHg, p<0.0001). FCT added to BOT caused a further increase in PAWP and Qs (both p<0.0001), while PVR was unchanged (p>0.1).
No difference was observed in the PAWP response to FCT, BOT or both between groups; no patients reached a PAWP ≥18 mmHg following FCT or BOT alone, but 4 (8%) patients did following the addition of FCT to BOT. No acute clinical adverse events were experienced by any patients.
Conclusions
None of the reported ASD patients presented with FCT criteria of post-capillary PH (that is a PAWP >18 mmHg). Even small rises in PVR may have significant implications on cardiovascular haemodynamics. In fact, patients with PVR <2 WU showed an increase in Qp/Qs, which remained above 1.5 in all patients, suggesting that they still had a distensible pulmonary circulation, whereas in almost all patients with a PVR ≥2 WU, the Qp/Qs fell to below 1.5.
Funding Acknowledgement
Type of funding sources: None. Figure 1
Collapse
Affiliation(s)
- M D'Alto
- AORN Ospedali dei Colli - Monaldi Hospital, Naples, Italy
| | - M Chessa
- IRCCS Policlinico San Donato, GUCH Unit, San Donato Milanese, Italy
| | - G Santoro
- G. Pasquinucci Hospital, Paediatric Cardiology, Massa, Italy
| | - M Giordano
- AORN Ospedali dei Colli - Monaldi Hospital, Naples, Italy
| | - G Gaio
- AORN Ospedali dei Colli - Monaldi Hospital, Naples, Italy
| | - E Romeo
- AORN Ospedali dei Colli - Monaldi Hospital, Naples, Italy
| | - P Argiento
- AORN Ospedali dei Colli - Monaldi Hospital, Naples, Italy
| | - J Wacker
- IRCCS Policlinico San Donato, GUCH Unit, San Donato Milanese, Italy
| | - F D'Aiello
- IRCCS Policlinico San Donato, GUCH Unit, San Donato Milanese, Italy
| | - B Sarubbi
- AORN Ospedali dei Colli - Monaldi Hospital, Naples, Italy
| | - M G Russo
- AORN Ospedali dei Colli - Monaldi Hospital, Naples, Italy
| | - P Golino
- AORN Ospedali dei Colli - Monaldi Hospital, Naples, Italy
| | - A Costantine
- Royal Brompton Hospital Imperial College London, GUCH Unit, London, United Kingdom
| | - R Naeije
- Erasme Hospital, Department of Pathophysiology, Bruxelles, Belgium
| | - K Dimopoulos
- Royal Brompton Hospital Imperial College London, GUCH Unit, London, United Kingdom
| |
Collapse
|
13
|
Licea-Haquet GL, Reyes-Aguilar A, Alcauter S, Giordano M. The Neural Substrate of Speech Act Recognition. Neuroscience 2021; 471:102-114. [PMID: 34332015 DOI: 10.1016/j.neuroscience.2021.07.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2021] [Revised: 07/20/2021] [Accepted: 07/21/2021] [Indexed: 11/30/2022]
Abstract
Pragmatic competence demands linguistic, but also communicative, social and cognitive competence. Successful use of language in social interaction requires mutual understanding of the speaker's intentions; without it, a conversation cannot proceed. The term speech act refers to what a speaker intends to accomplish when saying something. The purpose of this study was to contribute to the identification of the neural substrate of speech act recognition and to the characterization of the cognitive processes that may be involved. The recognition of speech acts resulted in greater activation of frontal regions, precuneus and posterior cingulate gyrus. From all cognitive and behavioral measures obtained, only the scores in mental flexibility predicted the change in blood oxygen level dependent (BOLD) signal in the precuneus. These results, support the idea that speech act recognition requires the inference of intention, executive functions, including memory and entails the activation of areas of social cognition that participate in several brain networks i.e., the Intention Processing, the Default Mode and Theory of Mind networks, and areas involved in planning and guiding behavior.
Collapse
Affiliation(s)
- G L Licea-Haquet
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología UNAM Campus Juriquilla, Querétaro, Mexico
| | - A Reyes-Aguilar
- Laboratorio de Neurocognición, Facultad de Psicología, Universidad Nacional Autónoma de México, CDMX, Mexico
| | - S Alcauter
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología UNAM Campus Juriquilla, Querétaro, Mexico
| | - M Giordano
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología UNAM Campus Juriquilla, Querétaro, Mexico.
| |
Collapse
|
14
|
Zaed I, Bossi B, Ganau M, Tinterri B, Giordano M, Chibbaro S. Current state of benefits of Enhanced Recovery After Surgery (ERAS) in spinal surgeries: A systematic review of the literature. Neurochirurgie 2021; 68:61-68. [PMID: 33901525 DOI: 10.1016/j.neuchi.2021.04.007] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2020] [Revised: 03/07/2021] [Accepted: 04/11/2021] [Indexed: 12/14/2022]
Abstract
INTRODUCTION Recent years have been characterized by a great technological and clinical development in spine surgery. In particular, enhanced recovery after surgery (ERAS) programs, started to gain interest also in this surgical field. Here we tried to analyse the current state of art of ERAS technique in spine surgery. MATERIAL AND METHOD A systematic review of the literature has been performed in order to find all the possible inclusions. Using the PRISMA guidelines, a search of the PubMed/Medline, Web of Science, Cochrane Reviews, Embase, Medline databases was conducted to identify all full-text articles in the English-language literature describing the use of ERAS programs or techniques for spine surgery in adult patients. RESULTS Out of the 827 studies found, only 21 met the inclusion criteria has been retained to be included in the present study. The most frequently benefits of ERAS protocols were shorter hospitalisations (n=15), and decreased complication rates (n=8) lower postoperative pain scores (n=4). These benefits were seen in the 3 main categories considered: lumbar spine surgeries, surgeries for correction of scoliosis or deformity, and surgeries of the cervical spine. CONCLUSION There are an arising amount of data showing that the use of ERAS programs could be helpful in reducing the days of hospitalizations and the number of complications for certain spinal procedures and in a highly selected group of patients. Despite the large interest on the topic; there is an important lack of high level of scientific evidences. Because of that, there is the need to encourage the design and creation of new randomized clinical trials that will validate the present findings.
Collapse
Affiliation(s)
- I Zaed
- Humanitas University, Via Rita Levi Montalcini, Pieve Emanuele (MI), Italy; Department of Neurosurgery, Humanitas Clinical and Research Center, Rozzano (MI), Italy.
| | - B Bossi
- Humanitas University, Via Rita Levi Montalcini, Pieve Emanuele (MI), Italy
| | - M Ganau
- Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
| | - B Tinterri
- Humanitas University, Via Rita Levi Montalcini, Pieve Emanuele (MI), Italy
| | - M Giordano
- Department of Neurosurgery, International Neuroscience Institute, Hannover, Germany
| | - S Chibbaro
- Department of Neurosurgery, Strasbourg University Hospitals, Strasbourg, France
| |
Collapse
|
15
|
D'Alto M, Chessa M, Gaio G, Santoro G, Giordano M, Romeo E, Argiento P, Wacker J, D'Aiello F, Sarubbi B, Russo M, Naeije R, Golino P. Response to fluid challenge in patients with atrial septal defect. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
A fluid challenge test (FCT) with a rapid infusion of saline allows for discrimination between pre- and post-capillary pulmonary hypertension (PH) and may unmask hidden post-capillary PH. Patients with atrial septal defect (ASD) may develop pre- or post-capillary PH after shunt closure respectively in case of pulmonary vascular disease or left ventricular disease.
Aim
To evaluate the haemodynamic changes of the pulmonary circulation in ASD patients undergoing percutaneous closure with indicated according to the current ESC guidelines.
Methods
Twenty-three patients (mean age 42.9±12.4 years; 15 female) underwent right heart catheterization in basal conditions and after FCT (volume loading with rapid saline infusion of 7 ml/kg in 10 min) before percutaneous closure of the ASD.
Right atrial pressure (RAP), systolic, mean and diastolic pulmonary arterial pressure (sPAP, mPAP and dPAP), pulmonary arterial wedge pressure (PAWP), cardiac output (CO), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR) and the ratio between pulmonary and systemic flow (QP/QS) were calculated four times: before and after inflating the sizing balloon both at baseline and immediately after FCT (Fig. 1).
Results
The patients had an increase in pressures and flows after FCT with open ASD: mPAP (18.7±4.4 vs 16.7±4.6 mmHg, p<0.001), PAWP (11.3±3.1 vs 9.2±3.0 mmHg, p<0.001), QP (12.5±2.3 vs 10.3±2.0 l/min, p<0.001), and QS (6.6±1.4 vs 5.9±1.2 l/min, p<0.001) but RAP remained unchanged (8.7±3.0 vs 8.3±2.4 mmHg, p=0.35). PVR (0.2±0.4 vs 0.8±0.3 Wood Units, p<0.001) and SVR (11.2±3.2 vs 12.5±3.2 Wood Units, p=0.02) decreased, and PVR/SVR (0.06±0.02 vs 0.06±0.3, p=0.25) remained unchanged. QP/QS increased in all patients after FCT (mean±SD: 2.0±0.4 vs 1.8±0.4, p<0.001).
During a temporary ASD closure by sizing balloon, the patients had increases of RAP (9.0±2.6 vs 7.6±2.6 mmHg, p<0.001) mPAP (19.5±4.0 vs 17.4±3.7 mmHg, p<0.001), PAWP (13.2±2.1 vs 11.2±2.9 mmHg, p<0.001), and CO (7.7±2.7 vs 6.8±2.3 l/min, p<0.001) after FCT. PVR remained unchanged (0.9±0.4 vs 1.1±0.6, p=0.12) and SVR reduced (9.8±2.7 vs 11.3±2.9, p<0.001) after FCT.
Conclusions
None of the reported ASD patients presented with FCT criteria of post-capillary PH (that is a PAWP >18 mmHg). The FCT was associated with an increase in QP/QS suggesting that the patients still had a distensible pulmonary circulation. Further studies are needed to explore the relevance of a FCT in ASD patients, particularly those with higher PVR values.
Figure 1
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- M D'Alto
- AO dei Colli-Monaldi Hospital, Naples, Italy
| | - M Chessa
- IRCCS Policlinico San Donato, GUCH Unit, San Donato Milanese, Italy
| | - G Gaio
- AO dei Colli-Monaldi Hospital, Naples, Italy
| | - G Santoro
- G. Pasquinucci Hospital, Paediatric Cardiology, Massa, Italy
| | - M Giordano
- AO dei Colli-Monaldi Hospital, Naples, Italy
| | - E Romeo
- AO dei Colli-Monaldi Hospital, Naples, Italy
| | - P Argiento
- AO dei Colli-Monaldi Hospital, Naples, Italy
| | - J Wacker
- IRCCS Policlinico San Donato, GUCH Unit, San Donato Milanese, Italy
| | - F D'Aiello
- IRCCS Policlinico San Donato, GUCH Unit, San Donato Milanese, Italy
| | - B Sarubbi
- AO dei Colli-Monaldi Hospital, Naples, Italy
| | - M.G Russo
- AO dei Colli-Monaldi Hospital, Naples, Italy
| | - R Naeije
- Erasme Hospital, Department of Pathophysiology, Bruxelles, Belgium
| | - P Golino
- AO dei Colli-Monaldi Hospital, Naples, Italy
| |
Collapse
|
16
|
Giordano M, Kapas K, Katz S, Nogradi D, Pasztor A. Effect of stout smearing on the phase diagram from multiparameter reweighting in lattice QCD. Int J Clin Exp Med 2020. [DOI: 10.1103/physrevd.102.034503] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
17
|
Borelli B, Fontana E, Giordano M, Antoniotti C, Bergamo F, Murgioni S, Pietrantonio F, Morano F, Tamburini E, Boccaccino A, Santini D, Conca V, Pella N, Maiello E, Ugolini C, Fontanini G, Falcone A, Nyamundanda G, Sadanandam A, Cremolini C. SO-20 Consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the TRIBE2 study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
18
|
Chávez-Pichardo ME, Reyes-Bravo DY, Mendoza-Trejo MS, Marín-López AG, Giordano M, Hernández-Chan N, Domínguez-Marchan K, Ortega-Rosales LC, Rodríguez VM. Brain alterations in GABA, glutamate and glutamine markers after chronic atrazine exposure in the male albino rat. Arch Toxicol 2020; 94:3217-3230. [PMID: 32561961 DOI: 10.1007/s00204-020-02806-2] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2020] [Accepted: 06/15/2020] [Indexed: 11/28/2022]
Abstract
Atrazine (ATR; 2-chloro-4-ethylamino-6-isopropylamino-s-triazine) is an herbicide widely used to kill annual grasses and broadleaf weeds in crops such as corn, sorghum, and sugarcane. Studies in rodents have shown that chronic ATR exposure is associated with alterations in the nigrostriatal dopaminergic pathway such as hyperactivity, decreased striatal dopamine levels, and diminished numbers of tyrosine hydroxylase positive cells in substantia nigra pars compacta. However, the effects of ATR on neurotransmitters such as GABA and glutamate have been scarcely studied. To evaluate the impact of ATR on motor and anxiety tasks, tissue levels of GABA, glutamate, glutamine, and extracellular and potassium-evoked release of glutamate in the striatum, we daily exposed Sprague-Dawley male rats to 1 or 10 mg ATR/kg of body weight for 12-14 months. As previously reported, chronic ATR exposure causes hyperactivity in the group exposed to 10 mg ATR/kg and increased anxiety in both groups exposed to ATR. GABA, glutamate, and glutamine levels were differentially altered in brain regions related to nigrostriatal and mesolimbic systems, the amygdala, and the prefrontal cortex. The groups exposed to 10 mg ATR/kg showed increased extracellular levels and release of glutamate in the striatum. These neurochemical alterations could underlie the behavioral changes observed in rats. These results indicate that chronic exposure to the herbicide ATR disrupts the neurochemistry of several brain structures and could be a risk factor for the development of neurodegenerative diseases.
Collapse
Affiliation(s)
- M E Chávez-Pichardo
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Boulevard Juriquilla 3001, Querétaro, Querétaro, 76230, México
| | - D Y Reyes-Bravo
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Boulevard Juriquilla 3001, Querétaro, Querétaro, 76230, México
| | - M S Mendoza-Trejo
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Boulevard Juriquilla 3001, Querétaro, Querétaro, 76230, México
| | - A G Marín-López
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Boulevard Juriquilla 3001, Querétaro, Querétaro, 76230, México
| | - M Giordano
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Boulevard Juriquilla 3001, Querétaro, Querétaro, 76230, México
| | - N Hernández-Chan
- Facultad de Ingeniería, Universidad Autónoma de Querétaro, Querétaro, México
| | - K Domínguez-Marchan
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Boulevard Juriquilla 3001, Querétaro, Querétaro, 76230, México
| | - L C Ortega-Rosales
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Boulevard Juriquilla 3001, Querétaro, Querétaro, 76230, México
| | - V M Rodríguez
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Boulevard Juriquilla 3001, Querétaro, Querétaro, 76230, México.
| |
Collapse
|
19
|
Ciarambino T, Schettino F, Giordano M, Politi C. NEW PARAMETERS IN NON-INVASIVE VENTILATION FOR THE INTERNETIST? Chest 2020. [DOI: 10.1016/j.chest.2020.05.356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
20
|
Caffo O, Palesandro E, Nole F, Gasparro D, Mucciarini C, Aieta M, Zagonel V, Iacovelli R, De Giorgi U, Rossetti S, Fratino L, Ermacora P, Nicodemo M, Giordano M, Sartori D, Scapoli D, Verri E, Maines F, Pappagallo G, Aglietta M. Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz248.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Cazzaniga M, Pronzato P, Del Mastro L, Natoli C, Montemurro F, Bisagni G, Blasi L, Turletti A, Giordano M, Biganzoli L, Michelotti A, Garrone O, Marchetti P, Riccardi F, Bernardo A, Livi L, Cognetti F, Donadio M, Romagnoli E, Mustacchi G. Changes in hormone-receptor status in luminal breast cancers between primary tumour and metastases: Results of the observational cohort GIM-13 AMBRA study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Fontana E, Nyamundanda G, Cunningham D, Jonker D, Siu L, Tu D, Sclafani F, Eason K, Ragulan C, Hulkki-Wilson S, Loree J, Giordano M, Lawrence P, Shapiro J, Cremolini C, Starling N, Pietrantonio F, Trusolino L, O’Callaghan C, Sadanandam A. Association between transit-amplifying signature and outcomes of patients treated with anti-epidermal growth factor receptor (EGFR) therapy in colorectal cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz246.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
23
|
Agostini M, Bakalyarov AM, Balata M, Barabanov I, Baudis L, Bauer C, Bellotti E, Belogurov S, Bettini A, Bezrukov L, Borowicz D, Brudanin V, Brugnera R, Caldwell A, Cattadori C, Chernogorov A, Comellato T, D'Andrea V, Demidova EV, Di Marco N, Domula A, Doroshkevich E, Egorov V, Falkenstein R, Fomina M, Gangapshev A, Garfagnini A, Giordano M, Grabmayr P, Gurentsov V, Gusev K, Hakenmüller J, Hegai A, Heisel M, Hemmer S, Hiller R, Hofmann W, Hult M, Inzhechik LV, Janicskó Csáthy J, Jochum J, Junker M, Kazalov V, Kermaïdic Y, Kihm T, Kirpichnikov IV, Kirsch A, Kish A, Klimenko A, Kneißl R, Knöpfle KT, Kochetov O, Kornoukhov VN, Krause P, Kuzminov VV, Laubenstein M, Lazzaro A, Lindner M, Lippi I, Lubashevskiy A, Lubsandorzhiev B, Lutter G, Macolino C, Majorovits B, Maneschg W, Miloradovic M, Mingazheva R, Misiaszek M, Moseev P, Nemchenok I, Panas K, Pandola L, Pelczar K, Pertoldi L, Piseri P, Pullia A, Ransom C, Riboldi S, Rumyantseva N, Sada C, Sala E, Salamida F, Schmitt C, Schneider B, Schönert S, Schütz AK, Schulz O, Schwarz M, Schwingenheuer B, Selivanenko O, Shevchik E, Shirchenko M, Simgen H, Smolnikov A, Stanco L, Stukov D, Vanhoefer L, Vasenko AA, Veresnikova A, von Sturm K, Wagner V, Wegmann A, Wester T, Wiesinger C, Wojcik M, Yanovich E, Zhitnikov I, Zhukov SV, Zinatulina D, Zschocke A, Zsigmond AJ, Zuber K, Zuzel G. Probing Majorana neutrinos with double-β decay. Science 2019; 365:1445-1448. [PMID: 31488705 DOI: 10.1126/science.aav8613] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2018] [Accepted: 08/20/2019] [Indexed: 11/02/2022]
Abstract
A discovery that neutrinos are Majorana fermions would have profound implications for particle physics and cosmology. The Majorana character of neutrinos would make possible the neutrinoless double-β (0νββ) decay, a matter-creating process without the balancing emission of antimatter. The GERDA Collaboration searches for the 0νββ decay of 76Ge by operating bare germanium detectors in an active liquid argon shield. With a total exposure of 82.4 kg⋅year, we observe no signal and derive a lower half-life limit of T 1/2 > 0.9 × 1026 years (90% C.L.). Our T 1/2 sensitivity, assuming no signal, is 1.1 × 1026 years. Combining the latter with those from other 0νββ decay searches yields a sensitivity to the effective Majorana neutrino mass of 0.07 to 0.16 electron volts.
Collapse
Affiliation(s)
- M Agostini
- Physik Department, Technische Universität München, D-85748 Munich, Germany
| | - A M Bakalyarov
- National Research Centre "Kurchatov Institute," Moscow 123182, Russia
| | - M Balata
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, I-67100 Assergi, Italy
| | - I Barabanov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - L Baudis
- Physik Institut der Universität Zürich, CH-8057 Zurich, Switzerland
| | - C Bauer
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - E Bellotti
- Dipartimento di Fisica, Università Milano Bicocca, I-20126 Milan, Italy.,INFN Milano Bicocca, I-20126 Milan, Italy
| | - S Belogurov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia.,Institute for Theoretical and Experimental Physics, Moscow 117259, Russia
| | - A Bettini
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35121 Padua, Italy.,INFN Padova, I-35131 Padua, Italy
| | - L Bezrukov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - D Borowicz
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - V Brudanin
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - R Brugnera
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35121 Padua, Italy.,INFN Padova, I-35131 Padua, Italy
| | - A Caldwell
- Max-Planck-Institut für Physik, D-80805 Munich, Germany
| | | | - A Chernogorov
- Institute for Theoretical and Experimental Physics, Moscow 117259, Russia
| | - T Comellato
- Physik Department, Technische Universität München, D-85748 Munich, Germany
| | - V D'Andrea
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell'Aquila, I-67100 L'Aquila, Italy
| | - E V Demidova
- Institute for Theoretical and Experimental Physics, Moscow 117259, Russia
| | - N Di Marco
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, I-67100 Assergi, Italy
| | - A Domula
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, D-01069 Dresden, Germany
| | - E Doroshkevich
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - V Egorov
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - R Falkenstein
- Physikalisches Institut, Eberhard Karls Universität Tübingen, D-72076 Tübingen, Germany
| | - M Fomina
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - A Gangapshev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - A Garfagnini
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35121 Padua, Italy.,INFN Padova, I-35131 Padua, Italy
| | - M Giordano
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell'Aquila, I-67100 L'Aquila, Italy
| | - P Grabmayr
- Physikalisches Institut, Eberhard Karls Universität Tübingen, D-72076 Tübingen, Germany
| | - V Gurentsov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - K Gusev
- Physik Department, Technische Universität München, D-85748 Munich, Germany.,National Research Centre "Kurchatov Institute," Moscow 123182, Russia.,Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - J Hakenmüller
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - A Hegai
- Physikalisches Institut, Eberhard Karls Universität Tübingen, D-72076 Tübingen, Germany
| | - M Heisel
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - S Hemmer
- INFN Padova, I-35131 Padua, Italy
| | - R Hiller
- Physik Institut der Universität Zürich, CH-8057 Zurich, Switzerland
| | - W Hofmann
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - M Hult
- European Commission, JRC-Geel, B-2440 Geel, Belgium
| | - L V Inzhechik
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - J Janicskó Csáthy
- Physik Department, Technische Universität München, D-85748 Munich, Germany
| | - J Jochum
- Physikalisches Institut, Eberhard Karls Universität Tübingen, D-72076 Tübingen, Germany
| | - M Junker
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, I-67100 Assergi, Italy
| | - V Kazalov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - Y Kermaïdic
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - T Kihm
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - I V Kirpichnikov
- Institute for Theoretical and Experimental Physics, Moscow 117259, Russia
| | - A Kirsch
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - A Kish
- Physik Institut der Universität Zürich, CH-8057 Zurich, Switzerland
| | - A Klimenko
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany.,Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - R Kneißl
- Max-Planck-Institut für Physik, D-80805 Munich, Germany
| | - K T Knöpfle
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany.
| | - O Kochetov
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - V N Kornoukhov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia.,Institute for Theoretical and Experimental Physics, Moscow 117259, Russia
| | - P Krause
- Physik Department, Technische Universität München, D-85748 Munich, Germany
| | - V V Kuzminov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - M Laubenstein
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, I-67100 Assergi, Italy
| | - A Lazzaro
- Physik Department, Technische Universität München, D-85748 Munich, Germany
| | - M Lindner
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - I Lippi
- INFN Padova, I-35131 Padua, Italy
| | - A Lubashevskiy
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - B Lubsandorzhiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - G Lutter
- European Commission, JRC-Geel, B-2440 Geel, Belgium
| | - C Macolino
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, I-67100 Assergi, Italy
| | - B Majorovits
- Max-Planck-Institut für Physik, D-80805 Munich, Germany
| | - W Maneschg
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - M Miloradovic
- Physik Institut der Universität Zürich, CH-8057 Zurich, Switzerland
| | - R Mingazheva
- Physik Institut der Universität Zürich, CH-8057 Zurich, Switzerland
| | - M Misiaszek
- Institute of Physics, Jagiellonian University, Cracow 40-348, Poland
| | - P Moseev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - I Nemchenok
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - K Panas
- Institute of Physics, Jagiellonian University, Cracow 40-348, Poland
| | - L Pandola
- INFN Laboratori Nazionali del Sud, I-95123 Catania, Italy
| | - K Pelczar
- INFN Laboratori Nazionali del Gran Sasso and Gran Sasso Science Institute, I-67100 Assergi, Italy
| | - L Pertoldi
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35121 Padua, Italy.,INFN Padova, I-35131 Padua, Italy
| | - P Piseri
- Dipartimento di Fisica, Università degli Studi di Milano e INFN Milano, I-20133 Milan, Italy
| | - A Pullia
- Dipartimento di Fisica, Università degli Studi di Milano e INFN Milano, I-20133 Milan, Italy
| | - C Ransom
- Physik Institut der Universität Zürich, CH-8057 Zurich, Switzerland
| | - S Riboldi
- Dipartimento di Fisica, Università degli Studi di Milano e INFN Milano, I-20133 Milan, Italy
| | - N Rumyantseva
- National Research Centre "Kurchatov Institute," Moscow 123182, Russia.,Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - C Sada
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35121 Padua, Italy.,INFN Padova, I-35131 Padua, Italy
| | - E Sala
- Max-Planck-Institut für Physik, D-80805 Munich, Germany
| | - F Salamida
- INFN Laboratori Nazionali del Gran Sasso and Università degli Studi dell'Aquila, I-67100 L'Aquila, Italy
| | - C Schmitt
- Physikalisches Institut, Eberhard Karls Universität Tübingen, D-72076 Tübingen, Germany
| | - B Schneider
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, D-01069 Dresden, Germany
| | - S Schönert
- Physik Department, Technische Universität München, D-85748 Munich, Germany
| | - A-K Schütz
- Physikalisches Institut, Eberhard Karls Universität Tübingen, D-72076 Tübingen, Germany
| | - O Schulz
- Max-Planck-Institut für Physik, D-80805 Munich, Germany
| | - M Schwarz
- Physik Department, Technische Universität München, D-85748 Munich, Germany
| | | | - O Selivanenko
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - E Shevchik
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - M Shirchenko
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - H Simgen
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - A Smolnikov
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany.,Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - L Stanco
- INFN Padova, I-35131 Padua, Italy
| | - D Stukov
- National Research Centre "Kurchatov Institute," Moscow 123182, Russia
| | - L Vanhoefer
- Max-Planck-Institut für Physik, D-80805 Munich, Germany
| | - A A Vasenko
- Institute for Theoretical and Experimental Physics, Moscow 117259, Russia
| | - A Veresnikova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - K von Sturm
- Dipartimento di Fisica e Astronomia dell'Università di Padova, I-35121 Padua, Italy.,INFN Padova, I-35131 Padua, Italy
| | - V Wagner
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - A Wegmann
- Max-Planck-Institut für Kernphysik, D-69117 Heidelberg, Germany
| | - T Wester
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, D-01069 Dresden, Germany
| | - C Wiesinger
- Physik Department, Technische Universität München, D-85748 Munich, Germany
| | - M Wojcik
- Institute of Physics, Jagiellonian University, Cracow 40-348, Poland
| | - E Yanovich
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow 117312, Russia
| | - I Zhitnikov
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - S V Zhukov
- National Research Centre "Kurchatov Institute," Moscow 123182, Russia
| | - D Zinatulina
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - A Zschocke
- Physikalisches Institut, Eberhard Karls Universität Tübingen, D-72076 Tübingen, Germany
| | - A J Zsigmond
- Max-Planck-Institut für Physik, D-80805 Munich, Germany
| | - K Zuber
- Institut für Kern- und Teilchenphysik, Technische Universität Dresden, D-01069 Dresden, Germany
| | - G Zuzel
- Institute of Physics, Jagiellonian University, Cracow 40-348, Poland
| | | |
Collapse
|
24
|
Mateus-Reguengo L, Barbosa-Pereira L, Rembangouet W, Bertolino M, Giordano M, Rojo-Poveda O, Zeppa G. Food applications of Irvingia gabonensis (Aubry-Lecomte ex. O'Rorke) Baill., the 'bush mango': A review. Crit Rev Food Sci Nutr 2019; 60:2446-2459. [PMID: 31366215 DOI: 10.1080/10408398.2019.1646704] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Irvingia gabonensis, also known as 'bush mango', is a multipurpose fruit tree, native to tropical Africa. It is a priority indigenous fruit tree in western and central Africa since its wood is used for making utensils and fruits are mostly used as food and medicine. The objective of this work is to provide an updated review of the available knowledge about physicochemical characteristics of I. gabonensis fruit in order to evaluate its potential use in the food industry. The fruit mesocarp contains various phytochemicals and ascorbic acid concentration higher than some vitamin C rich fruits, then it is consumed fresh or dried, used to produce juice and wine, or as a flavourant. I. gabonensis fruit kernel is rich in oil (63%-69% crude fat), mainly composed of myristic and lauric acids. Its triacylglycerol composition and, resultantly, melting curve and polymorphism indicate an aptitude for diverse applications, as it is solid at room temperature. Forty-one phenolic compounds were identified in the seeds and derived extracts and supplements, being ellagic acid and its derivates the most present. This review enhances our knowledge about nutritional content and health benefits of I. gabonensis whole fruit, especially its pulp and seed, evidencing the need for safer and more efficient production of value-added products.
Collapse
Affiliation(s)
- L Mateus-Reguengo
- Department of Agriculture, Forest, and Food Sciences (DISAFA), University of Turin, Turin, TO, Italy
| | - L Barbosa-Pereira
- Department of Agriculture, Forest, and Food Sciences (DISAFA), University of Turin, Turin, TO, Italy
| | | | - M Bertolino
- Department of Agriculture, Forest, and Food Sciences (DISAFA), University of Turin, Turin, TO, Italy
| | - M Giordano
- Department of Agriculture, Forest, and Food Sciences (DISAFA), University of Turin, Turin, TO, Italy
| | - O Rojo-Poveda
- Department of Agriculture, Forest, and Food Sciences (DISAFA), University of Turin, Turin, TO, Italy
| | - G Zeppa
- Department of Agriculture, Forest, and Food Sciences (DISAFA), University of Turin, Turin, TO, Italy
| |
Collapse
|
25
|
Giordano M, Licea-Haquet G, Navarrete E, Valles-Capetillo E, Lizcano-Cortés F, Carrillo-Peña A, Zamora-Ursulo A. Comparison between the Short Story Task and the Reading the Mind in the Eyes Test for evaluating Theory of Mind: A replication report. Cogent Psychology 2019. [DOI: 10.1080/23311908.2019.1634326] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Affiliation(s)
- M. Giordano
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, UNAM, Blvd. Juriquilla 3001, Juriquilla, Qro 76230, Mexico
| | - G. Licea-Haquet
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, UNAM, Blvd. Juriquilla 3001, Juriquilla, Qro 76230, Mexico
| | - E. Navarrete
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, UNAM, Blvd. Juriquilla 3001, Juriquilla, Qro 76230, Mexico
| | - E. Valles-Capetillo
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, UNAM, Blvd. Juriquilla 3001, Juriquilla, Qro 76230, Mexico
| | - F. Lizcano-Cortés
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, UNAM, Blvd. Juriquilla 3001, Juriquilla, Qro 76230, Mexico
| | - A. Carrillo-Peña
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, UNAM, Blvd. Juriquilla 3001, Juriquilla, Qro 76230, Mexico
| | - A. Zamora-Ursulo
- Departamento de Neurobiología Conductual y Cognitiva, Instituto de Neurobiología, UNAM, Blvd. Juriquilla 3001, Juriquilla, Qro 76230, Mexico
| |
Collapse
|
26
|
Giordano M, Aulisa AG, Guzzanti V, Careri S, Krzysztofiak A, Toniolo RM. Managing of musculoskeletal infections in children. Eur Rev Med Pharmacol Sci 2019; 23:179-186. [PMID: 30977884 DOI: 10.26355/eurrev_201904_17488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Epidemiological features of musculoskeletal infections are in continuous evolution. The incidence of emerging causative pathogen is arising. Nevertheless, up to 50% of osteoarticular infections shows negative cultures. Septic arthritis, with or without concurrent osteomyelitis, are most common in newborn while osteomyelitis frequently affects older patients. We retrospectively analyzed all the children affected by musculoskeletal infections treated at the Children's Hospital Bambino Gesù in ten years, focusing on the results of an early diagnostic and therapeutic management. MATERIALS AND METHODS The study population consists of 150 children with acute septic arthritis, osteomyelitis and discitis, treated from 2006 to 2016, excluding patients with less than 12 months of follow-up and previous treatment sustained in others hospitals. A wide spectrum of data has been extracted from clinical charts, laboratory studies and imaging. Patients were categorized into 3 groups on the base of their age. The diagnostic and therapeutic protocol consisted of intravenous empirical treatment while diagnosis was ongoing then switched to oral treatment, according to the pathogen and the systemic symptoms. RESULTS Only 31% of pathogens were identified. The most common was Staphylococcus aureus methicillin-sensible (MSSA) but an increase of cases caused by Kingella Kingae and Staphylococcus aureus methicillin-resistant (MRSA) was observed. The mean antibiotic treatment was 6.8 weeks. It's important to underline a significant correlation between age and C-reactive protein serum levels. CONCLUSIONS Among others frequent pathogens, MRSA shows a high rate of physis involvement. Musculoskeletal infections represent a challenge in skeletally immature patients because of their potential severe complications. Timing of diagnosis and consequent targeted treatment is fundamental to avoid complications and functional sequelae.
Collapse
Affiliation(s)
- M Giordano
- Department of Orthopaedics and Traumatology, Institute of Scientific Research, Children's Hospital Bambino Gesù, Rome, Italy.
| | | | | | | | | | | |
Collapse
|
27
|
Cazzaniga M, Lania A, Destro M, Bandera M, Biasi G, Giordano M, Pagani O. The global care of young women with breast cancer: take care from cure to care. A multidisciplinary educational initiative. Breast 2019. [DOI: 10.1016/s0960-9776(19)30439-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
28
|
Cazzaniga ME, Blasi L, Pronzato P, Giordano M, Garrone O, Donadio M, Del Mastro L, Livi L, Natoli C, Michelotti A, Turletti A, Riccardi F, De Laurentiis M, Marchetti P, Montemurro F, Romagnoli E, De Placido S, Biganzoli L, Bologna A, Bria E, Mustacchi G. Abstract P4-13-04: Not presented. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-13-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was not presented at the conference.
Citation Format: Cazzaniga ME, Blasi L, Pronzato P, Giordano M, Garrone O, Donadio M, Del Mastro L, Livi L, Natoli C, Michelotti A, Turletti A, Riccardi F, De Laurentiis M, Marchetti P, Montemurro F, Romagnoli E, De Placido S, Biganzoli L, Bologna A, Bria E, Mustacchi G. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-13-04.
Collapse
Affiliation(s)
- ME Cazzaniga
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - L Blasi
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - P Pronzato
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - M Giordano
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - O Garrone
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - M Donadio
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - L Del Mastro
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - L Livi
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - C Natoli
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - A Michelotti
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - A Turletti
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - F Riccardi
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - M De Laurentiis
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - P Marchetti
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - F Montemurro
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - E Romagnoli
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - S De Placido
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - L Biganzoli
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - A Bologna
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - E Bria
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - G Mustacchi
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| |
Collapse
|
29
|
Silkin VA, Pautova LA, Giordano M, Chasovnikov VK, Vostokov SV, Podymov OI, Pakhomova SV, Moskalenko LV. Drivers of phytoplankton blooms in the northeastern Black Sea. Mar Pollut Bull 2019; 138:274-284. [PMID: 30660274 DOI: 10.1016/j.marpolbul.2018.11.042] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/11/2018] [Revised: 11/16/2018] [Accepted: 11/19/2018] [Indexed: 06/09/2023]
Abstract
In order to understand of the processes controlling phytoplankton successions in the NE Black Sea, long-term data series are needed. We compiled 15 years (2002-2017) of measurements from which the existence emerges of a tight link between phytoplankton species dominance and nutrients concentrations. The latter is strongly influenced by wind direction. The link between algal dominance and nutrients is mediated by the growth strategy adopted by algal species. In spring, when nutrients are abundant, small diatoms such as Pseudo-nitzschia pseudodelicatissima, with a "rapid growth strategy", prevail. In late spring and early summer, when N is low and P and Si are high, coccolithophorids such as Emiliania huxhleyi dominate, thanks to an "affinity growth strategy". Large diatoms, especially Pseudosolenia calcar-avis, dominate in summer and autumn, when their "storage growth strategy" allows the exploitation of discontinuous upwelling of nutrients. These seasonal changes of dominant species influence the structure of the food web.
Collapse
Affiliation(s)
- V A Silkin
- The Southern Branch of the P.P. Shirshov Institute of Oceanology RAS, Gelendzhik, Krasnodar region, Russia
| | - L A Pautova
- P.P. Shirshov Institute of Oceanology RAS, Nakhimovski av., Moscow, Russia
| | - M Giordano
- Laboratorio di Fisiologia delle Alghe e delle Piante, Dipartimento di Scienze della Vita e dell'Ambiente, Università Politecnica delle Marche, Ancona, Italy; STU-UNIVPM Joint Algal Research Center, Shantou, China; Institute of Microbiology, Academy of Sciences of the Czech Republic, Algatech, Trebon, Czech Republic; National Research Council, Institute of Marine Science ISMAR, Venezia, Italy.
| | - V K Chasovnikov
- The Southern Branch of the P.P. Shirshov Institute of Oceanology RAS, Gelendzhik, Krasnodar region, Russia
| | - S V Vostokov
- P.P. Shirshov Institute of Oceanology RAS, Nakhimovski av., Moscow, Russia
| | - O I Podymov
- The Southern Branch of the P.P. Shirshov Institute of Oceanology RAS, Gelendzhik, Krasnodar region, Russia
| | - S V Pakhomova
- P.P. Shirshov Institute of Oceanology RAS, Nakhimovski av., Moscow, Russia
| | - L V Moskalenko
- The Southern Branch of the P.P. Shirshov Institute of Oceanology RAS, Gelendzhik, Krasnodar region, Russia
| |
Collapse
|
30
|
Guida M, Maffucci D, Iannuzzi G, Giordano M, Luciano G, Di Benedetto L, Cantarella R, Rescigno A, Giugliano L. Successful pregnancy after uterine artery embolization for uterine arterovenous malformation: a rare case report. Int J Womens Health 2018; 10:745-750. [PMID: 30538584 PMCID: PMC6254590 DOI: 10.2147/ijwh.s182131] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Objective This paper reports on a rare case of pregnancy after uterine artery embolization (UAE) for uterine arteriovenous malformation (AVM). Debate exists about persistence of fertility in women after UAE. Adverse effects of this technique can modify both uterine echostructure, inducing necrosis and infarction, endometrial atrophy and uterine artery rupture, and ovarian reserve, causing persistent amenorrhea. Ovarian reserve appears to be affected by UAE in pre-menopausal women. However, younger ovaries (according to biological ovarian age) exhibit a greater capacity for recovery after ovarian damage. Therefore, larger studies are needed for more conclusive results. Case report A 28-year-old woman was admitted to our department due to life-threatening uterine bleeding, resulting in tachycardia, pallor, and sweating. The patient came with a history of two spontaneous miscarriages. After sonography and computed tomography, AVMs were identified at uterine fundus and anterior wall. Conclusion The pathogenesis of infertility after UAE is not yet known. The peculiarity of this case was that, only few months later, the patient became pregnant and gave birth to a live fetus at 37 weeks with cesarean delivery.
Collapse
Affiliation(s)
- M Guida
- Università degli studi di Salerno - Dipartimento di Medicina, Chirurgia e Odontoiatria "Scuola Medica Salernitana", Salerno, Italy,
| | - D Maffucci
- Università degli studi di Salerno - Dipartimento di Medicina, Chirurgia e Odontoiatria "Scuola Medica Salernitana", Salerno, Italy,
| | - G Iannuzzi
- Università degli studi di Salerno - Dipartimento di Medicina, Chirurgia e Odontoiatria "Scuola Medica Salernitana", Salerno, Italy,
| | - M Giordano
- Università degli studi di Salerno - Dipartimento di Medicina, Chirurgia e Odontoiatria "Scuola Medica Salernitana", Salerno, Italy,
| | - G Luciano
- Università degli studi di Salerno - Dipartimento di Medicina, Chirurgia e Odontoiatria "Scuola Medica Salernitana", Salerno, Italy,
| | - L Di Benedetto
- Università degli studi di Roma "La Sapienza" - Dipartimento di Scienze Medico-Chirurgiche e di Medicina Traslazionale - Facoltà di Medicina e Psicologia Azienda Ospedaliera Sant' Andrea, Rome, Italy
| | - R Cantarella
- Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi D'Aragona, Salerno, Italy
| | - A Rescigno
- Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi D'Aragona, Salerno, Italy
| | - L Giugliano
- Università degli studi di Salerno - Dipartimento di Medicina, Chirurgia e Odontoiatria "Scuola Medica Salernitana", Salerno, Italy,
| |
Collapse
|
31
|
Boldrini L, Bartoletti R, Giordano M, Manassero F, Selli C, Panichi M, Galli L, Farci F, Faviana P. C-MYC, HIF-1α, ERG, TKT, and GSTP1: an Axis in Prostate Cancer? Pathol Oncol Res 2018; 25:1423-1429. [PMID: 30357756 DOI: 10.1007/s12253-018-0479-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/29/2018] [Accepted: 10/04/2018] [Indexed: 12/13/2022]
Abstract
To analyze putative biomarkers for prostate cancer (PCA) characterization, the second leading cause of cancer-associated mortality in men. Quantification of the expression level of c-myc and HIF-1α was performed in 72 prostate cancer specimens. A cohort of 497 prostate cancer patients from The Cancer Genome Atlas (TCGA) database was further analyzed, in order to test our hypothesis. We found that high c-myc level was significantly associated with HIF-1α elevated expression (p = 0.008) in our 72 samples. Statistical analysis of 497 TCGA prostate cancer specimens confirmed the strong association (p = 0.0005) of c-myc and HIF-1α expression levels, as we found in our series. Moreover, we found high c-myc levels significantly associated with low Glutatione S-transferase P1 (GSTP1) expression (p = 0.01), with high Transketolase (TKT) expression (p < 0.0001). High TKT levels were found in TCGA samples with low GSTP1 mRNA (p < 0.0001), as shown for c-myc, and with ERG increased expression (p = 0.02). Finally, samples with low GSTP1 expression displayed higher ERG mRNA levels than samples with high GSTP1 score (p < 0.0001), as above shown for c-myc. Our study emphasizes the notion of a potential value of HIF-1α and c-myc as putative biomarkers in prostate cancer; moreover TCGA data analysis showed a putative crosstalk between c-myc, HIF-1α, ERG, TKT, and GSTP1, suggesting a potential use of this axis in prostate cancer.
Collapse
Affiliation(s)
- L Boldrini
- Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Via Roma 57, 56126, Pisa, Italy.
| | - R Bartoletti
- Department of Translational Research and New Technologies, University of Pisa, Pisa, Italy
| | - M Giordano
- Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Via Roma 57, 56126, Pisa, Italy
| | - F Manassero
- Division of Urology, Pisa University, Pisa, Italy
| | - C Selli
- Department of Translational Research and New Technologies, University of Pisa, Pisa, Italy
| | - M Panichi
- Department of Radiotherapy, Pisa University, Pisa, Italy
| | - L Galli
- Division of Medical Oncology, Pisa University, Pisa, Italy
| | - F Farci
- Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Via Roma 57, 56126, Pisa, Italy
| | - P Faviana
- Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Via Roma 57, 56126, Pisa, Italy
| |
Collapse
|
32
|
Loppi S, Kolosowska N, Kärkkäinen O, Korhonen P, Huuskonen M, Grubman A, Dhungana H, Wojciechowski S, Pomeshchik Y, Giordano M, Kagechika H, White A, Auriola S, Koistinaho J, Landreth G, Hanhineva K, Kanninen K, Malm T. HX600, a synthetic agonist for RXR-Nurr1 heterodimer complex, prevents ischemia-induced neuronal damage. Brain Behav Immun 2018; 73:670-681. [PMID: 30063972 PMCID: PMC8543705 DOI: 10.1016/j.bbi.2018.07.021] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/27/2018] [Revised: 07/14/2018] [Accepted: 07/25/2018] [Indexed: 01/16/2023] Open
Abstract
Ischemic stroke is amongst the leading causes of death and disabilities. The available treatments are suitable for only a fraction of patients and thus novel therapies are urgently needed. Blockage of one of the cerebral arteries leads to massive and persisting inflammatory reaction contributing to the nearby neuronal damage. Targeting the detrimental pathways of neuroinflammation has been suggested to be beneficial in conditions of ischemic stroke. Nuclear receptor 4A-family (NR4A) member Nurr1 has been shown to be a potent modulator of harmful inflammatory reactions, yet the role of Nurr1 in cerebral stroke remains unknown. Here we show for the first time that an agonist for the dimeric transcription factor Nurr1/retinoid X receptor (RXR), HX600, reduces microglia expressed proinflammatory mediators and prevents inflammation induced neuronal death in in vitro co-culture model of neurons and microglia. Importantly, HX600 was protective in a mouse model of permanent middle cerebral artery occlusion and alleviated the stroke induced motor deficits. Along with the anti-inflammatory capacity of HX600 in vitro, treatment of ischemic mice with HX600 reduced ischemia induced Iba-1, p38 and TREM2 immunoreactivities, protected endogenous microglia from ischemia induced death and prevented leukocyte infiltration. These anti-inflammatory functions were associated with reduced levels of brain lysophosphatidylcholines (lysoPCs) and acylcarnitines, metabolites related to proinflammatory events. These data demonstrate that HX600 driven Nurr1 activation is beneficial in ischemic stroke and propose that targeting Nurr1 is a novel candidate for conditions involving neuroinflammatory component.
Collapse
Affiliation(s)
- S. Loppi
- A. I. Virtanen Institute for Molecular Sciences, Biocenter Kuopio, University of Eastern Finland, Kuopio, Finland
| | - N. Kolosowska
- A. I. Virtanen Institute for Molecular Sciences, Biocenter Kuopio, University of Eastern Finland, Kuopio, Finland
| | - O. Kärkkäinen
- Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Finland
| | - P. Korhonen
- A. I. Virtanen Institute for Molecular Sciences, Biocenter Kuopio, University of Eastern Finland, Kuopio, Finland
| | - M. Huuskonen
- A. I. Virtanen Institute for Molecular Sciences, Biocenter Kuopio, University of Eastern Finland, Kuopio, Finland
| | - A. Grubman
- Department of Anatomy and Developmental Biology, Monash University, Clayton 3800, Australia
| | - H. Dhungana
- A. I. Virtanen Institute for Molecular Sciences, Biocenter Kuopio, University of Eastern Finland, Kuopio, Finland
| | - S. Wojciechowski
- A. I. Virtanen Institute for Molecular Sciences, Biocenter Kuopio, University of Eastern Finland, Kuopio, Finland
| | - Y. Pomeshchik
- A. I. Virtanen Institute for Molecular Sciences, Biocenter Kuopio, University of Eastern Finland, Kuopio, Finland
| | - M. Giordano
- A. I. Virtanen Institute for Molecular Sciences, Biocenter Kuopio, University of Eastern Finland, Kuopio, Finland
| | - H. Kagechika
- Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo, Japan
| | - A. White
- Cell and Molecular Biology, QIMR Berghofer Medical Research Institute, Herston, Qld 4006, Australia
| | - S. Auriola
- Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Finland
| | - J. Koistinaho
- A. I. Virtanen Institute for Molecular Sciences, Biocenter Kuopio, University of Eastern Finland, Kuopio, Finland,Neuroscience Center, University of Helsinki, Helsinki, Finland
| | - G. Landreth
- Stark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - K. Hanhineva
- Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Finland
| | - K. Kanninen
- A. I. Virtanen Institute for Molecular Sciences, Biocenter Kuopio, University of Eastern Finland, Kuopio, Finland
| | - T. Malm
- A. I. Virtanen Institute for Molecular Sciences, Biocenter Kuopio, University of Eastern Finland, Kuopio, Finland,Corresponding author at: A. I. Virtanen Institute for Molecular Science, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland. (T. Malm)
| |
Collapse
|
33
|
Giordano M, Villa A, Freddi S, Bianchi F, Cavallaro U. PO-287 A novel L1/STAT3 crosstalk drives ovarian cancer stem cell function. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
34
|
Di Marca S, Rando A, Cataudella E, Pulvirenti A, Alaimo S, Terranova V, Corriere T, Pisano M, Di Quattro R, Ronsisvalle ML, Giraffa CM, Giordano M, Stancanelli B, Malatino L. B-type natriuretic peptide may predict prognosis in older adults admitted with a diagnosis other than heart failure. Nutr Metab Cardiovasc Dis 2018; 28:636-642. [PMID: 29625779 DOI: 10.1016/j.numecd.2018.02.017] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Revised: 02/16/2018] [Accepted: 02/23/2018] [Indexed: 12/28/2022]
Abstract
BACKGROUND AND AIMS The diagnosis of heart failure (HF) in elderly patients is often difficult, due to overlap of typical signs and symptoms with those of comorbidities. B-type Natriuretic Peptide (BNP) predicts diagnosis and prognosis of HF, but little is known on its predictive role of short-term prognosis when admission diagnosis is other than HF. METHODS AND RESULTS We prospectively recruited 404 consecutive patients (aged≥65 years) hospitalized in the Unit of Internal Medicine, University of Catania, Catania, Italy, with an admission diagnosis other than HF. Clinical examination, laboratory data and BNP were evaluated at the admission. The predictive value of BNP and other variables for in-hospital mortality, thirty-day mortality and three month re-hospitalization was assessed. During hospitalization 48 (12%) patients died; by logistic regression analysis, in-hospital mortality was not predicted by BNP>600 pg/ml (OR = 1.36; CI 95% = 0.60-2.80; p = 0.4), while it was by chronic kidney disease (CKD, p < 0.001), WBC count (p < 0.001), immobilization syndrome (p < 0.008) and age (p = 0.012). After discharge, 54 patients (15%) died within 30 days; in these patients thirty-day mortality was significantly predicted by BNP>600 pg/ml (OR = 2.70; CI 95% = 1.40-5.00; p = 0.001), CKD (p < 0.001), malnutrition (p = 0.029) and age (p = 0.033). Re-hospitalized patients were 97 (32%); three month re-hospitalization was predicted by BNP>600 pg/ml (OR = 12.28; CI 95% = 6.00-24.90; p < 0.001) and anamnestic HF (p = 0.002). CONCLUSIONS Our study shows that BNP>600 pg/ml, CKD, malnutrition and age predict thirty-day mortality after discharge in elderly patients with an admission diagnosis other than HF, while CKD, WBC count, immobilization syndrome and age predict in-hospital mortality. Three-month re-hospitalization was predicted by BNP>600 pg/ml and anamnestic HF.
Collapse
Affiliation(s)
- S Di Marca
- Academic Unit of Internal Medicine, School of Emergency Medicine, Department of Clinical and Experimental Medicine, University of Catania, c/o Cannizzaro Hospital, Catania, Italy
| | - A Rando
- Academic Unit of Internal Medicine, School of Emergency Medicine, Department of Clinical and Experimental Medicine, University of Catania, c/o Cannizzaro Hospital, Catania, Italy
| | - E Cataudella
- Academic Unit of Internal Medicine, School of Emergency Medicine, Department of Clinical and Experimental Medicine, University of Catania, c/o Cannizzaro Hospital, Catania, Italy
| | - A Pulvirenti
- Unit of Bioinformatics, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
| | - S Alaimo
- Unit of Bioinformatics, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy
| | - V Terranova
- Academic Unit of Internal Medicine, School of Emergency Medicine, Department of Clinical and Experimental Medicine, University of Catania, c/o Cannizzaro Hospital, Catania, Italy
| | - T Corriere
- Academic Unit of Internal Medicine, School of Emergency Medicine, Department of Clinical and Experimental Medicine, University of Catania, c/o Cannizzaro Hospital, Catania, Italy
| | - M Pisano
- Academic Unit of Internal Medicine, School of Emergency Medicine, Department of Clinical and Experimental Medicine, University of Catania, c/o Cannizzaro Hospital, Catania, Italy
| | - R Di Quattro
- Academic Unit of Internal Medicine, School of Emergency Medicine, Department of Clinical and Experimental Medicine, University of Catania, c/o Cannizzaro Hospital, Catania, Italy
| | - M L Ronsisvalle
- Academic Unit of Internal Medicine, School of Emergency Medicine, Department of Clinical and Experimental Medicine, University of Catania, c/o Cannizzaro Hospital, Catania, Italy
| | - C M Giraffa
- Academic Unit of Internal Medicine, School of Emergency Medicine, Department of Clinical and Experimental Medicine, University of Catania, c/o Cannizzaro Hospital, Catania, Italy
| | - M Giordano
- School of Emergency Medicine, Department of Medical, Surgical, Neurologic, Metabolic and Geriatric Sciences, Second University of Naples, Naples, Italy
| | - B Stancanelli
- Academic Unit of Internal Medicine, School of Emergency Medicine, Department of Clinical and Experimental Medicine, University of Catania, c/o Cannizzaro Hospital, Catania, Italy
| | - L Malatino
- Academic Unit of Internal Medicine, School of Emergency Medicine, Department of Clinical and Experimental Medicine, University of Catania, c/o Cannizzaro Hospital, Catania, Italy.
| |
Collapse
|
35
|
Giordano M, Moretto R, Giannini R, Zucchelli G, Pietrantonio F, Antoniotti C, Ugolini C, Morano F, Marmorino F, Sensi E, Belfiore A, Rossini D, Lupi C, Masi G, Borelli B, Ongaro E, Boccaccino A, Falcone A, Cremolini C, Fontanini G. Molecular characterization of immune microenvironment in colorectal cancers with microsatellite instability by digital RNA counting. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy150.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
36
|
De Palo T, Giordano M, Bellantuono R, Colella V, Troise D, Palumbo F, Caringella D. Therapeutic Apheresis in Children: Experience in a Pediatric Dialysis Center. Int J Artif Organs 2018. [DOI: 10.1177/039139880002301209] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The use of apheretic procedures in pediatric patients has always been restricted by technical difficulties and the low incidence of diseases requiring this kind of treatment. The aim of the present study was to describe the solutions adopted to solve technical difficulties related to priming, vascular access and monitoring and then to evaluate clinical results. Between 1982 and 2000, 51 consecutive children (28 male, 23 female) with a mean age of 4.9 ± 4.8 years (3 months – 14.8 years) and a mean weight of 19.7 ± 12.8 kg (5 – 52 kg), with renal and/or extra-renal diseases requiring apheretic procedures were selected for the study. The overall number of procedures performed were: 226 plasma-exchange (PE), 6 LDL-apheresis (LDL-A) and 8 protein A immunoadsorption (IAPA) sessions. Our therapeutic protocol involves hematic flux of 20 – 100 ml/min and ultrafiltration of 5–20 ml/min. In each 70–95 minute session we exchanged plasmatic volume with fresh frozen plasma or with a solution of 6% albumin in lactated Ringer's, using heparin (10–20 UI/kg/h). We used Paired Filtration Dialysis Monitor in PE and LDL-A; Citem 10 in IAPA. As plasma separator, we used a filter made of polypropylene, 0.2 m2 surface, 30 ml priming (Hemaplex BT 900). Hemolytic uremic syndrome was the most commonly treated disease (18/51 cases) with good results in 10/18 cases. We recorded, good results in vasculitis as well, in one girl with focal glomerulosclerosis in transplanted kidney and rapid improvement in all children with Guillaine-Barré Syndrome. PE treatment was effective in metabolic disorders such as tirosynemia and familiar hypercolesterolemia. Only 4/12 patients with acute liver failure due to viral hepatitis recovered. We had poor results in the remaining eight cases. Complications were rare and no viral infection was found in any patient. Our data show that it is possible to use these procedures in pediatric patients even though clinical indications and real effectiveness still need to be cleared up.
Collapse
Affiliation(s)
- T. De Palo
- Pediatric Nephrology and Dialysis, Children Hospital Giovanni XXIII, Bari - Italy
| | - M. Giordano
- Pediatric Nephrology and Dialysis, Children Hospital Giovanni XXIII, Bari - Italy
| | - R. Bellantuono
- Pediatric Nephrology and Dialysis, Children Hospital Giovanni XXIII, Bari - Italy
| | - V. Colella
- Pediatric Nephrology and Dialysis, Children Hospital Giovanni XXIII, Bari - Italy
| | - D. Troise
- Pediatric Cardiac Surgery, Children Hospital Giovanni XXIII, Bari - Italy
| | - F. Palumbo
- Institute of Urology, University of Bari, Bari - Italy
| | - D.A. Caringella
- Pediatric Nephrology and Dialysis, Children Hospital Giovanni XXIII, Bari - Italy
| |
Collapse
|
37
|
Bizzarri C, Lonero A, Delvecchio M, Cavallo L, Faienza MF, Giordano M, Dello Strologo L, Cappa M. Growth hormone treatment improves final height and nutritional status of children with chronic kidney disease and growth deceleration. J Endocrinol Invest 2018; 41:325-331. [PMID: 28819753 DOI: 10.1007/s40618-017-0745-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2017] [Accepted: 08/08/2017] [Indexed: 12/19/2022]
Abstract
PURPOSE Growth retardation is a common complication of chronic kidney disease (CKD) in children. Treatment with recombinant human growth hormone (rhGH) has been used to help short children with CKD to attain a height more in keeping with their age group, but the scientific evidence regarding the effect of rhGH on final height is scarce. METHODS Final heights of children with CKD receiving rhGH treatment (cases) were compared with final heights of a matched cohort of children with CKD that did not receive rhGH therapy (controls). RESULTS Sixty-eight rhGH-treated cases (44 boys) were compared with 92 untreated controls (60 boys). Mean duration of rhGH therapy was 4.2 ± 0.9 years; rhGH dose was 0.3 ± 0.07 mg/kg/week. Height SDS at baseline was lower in rhGH-treated patients than in controls (-2.00 ± 1.02 versus -0.96 ± 1.11, p < 0.001). Baseline height SDS was significantly lower than target height SDS in both groups. Height SDS significantly improved from baseline to final height attainment in rhGH-treated patients, while it slightly decreased in controls (mean SDS variation 0.69 ± 1.05 in rhGH-treated cases versus -0.15 ± 1.2 in controls). Final height SDS was -1.25 ± 1.06 in rhGH-treated cases and -1.06 ± 1.17 in controls (p = 0.29). Target adjusted final height SDS was -0.91 ± 1.03 in rhGH-treated cases and -0.61 ± 1.17 in controls (p = 0.1). CONCLUSIONS Long-term rhGH therapy is able to reduce the linear growth deceleration of children with CKD, and ultimately to improve their final height, reducing the difference with target height.
Collapse
Affiliation(s)
- C Bizzarri
- Unit of Endocrinology and Diabetes, Bambino Gesù Children's Hospital, IRCCS, Piazza S. Onofrio 4, 00165, Rome, Italy.
| | - A Lonero
- Department of Biomedicine and Human Oncology/Pediatric Section, University A. Moro, Bari, Italy
| | - M Delvecchio
- Department of Biomedicine and Human Oncology/Pediatric Section, University A. Moro, Bari, Italy
| | - L Cavallo
- Department of Biomedicine and Human Oncology/Pediatric Section, University A. Moro, Bari, Italy
| | - M F Faienza
- Department of Biomedicine and Human Oncology/Pediatric Section, University A. Moro, Bari, Italy
| | - M Giordano
- Pediatric Nephrology and Dialysis Unit, Children's Hospital Giovanni XXIII, Bari, Italy
| | - L Dello Strologo
- Unit of Pediatric Nephrology and Renal Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - M Cappa
- Unit of Endocrinology and Diabetes, Bambino Gesù Children's Hospital, IRCCS, Piazza S. Onofrio 4, 00165, Rome, Italy
| |
Collapse
|
38
|
Ardizzoni A, Bidoli P, Chiari R, Bonomi L, Turci D, Landi L, Toschi L, De Tursi M, Francini G, Giordano M, Alabiso O, De Censi A, Livi L, Berruti A, Minelli M, Ricevuto E, Illiano A, Puppo G, Delmonte A, Galetta D. MA 02.05 Nivolumab in Advanced Non-Squamous NSCLC Patients with KRAS Mutations: Results from the Italian Expanded Access Program (EAP). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.454] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
39
|
Pronzato P, Mustacchi G, Riccardi F, Turletti A, Michelotti A, Natoli C, Livi L, Del Mastro L, Donadio M, Garrone O, Giordano M, De Laurentiis M, Marchetti P, Montemurro F, Romagnoli E, De Placido S, Biganzoli L, Cazzaniga M. Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Mustacchi G, Cazzaniga M, Giordano M, Garrone O, Donadio M, Del Mastro L, Livi L, Natoli C, Michelotti A, Turletti A, Riccardi F, Marchetti P, Montemurro F, Romagnoli E, De Placido S, Biganzoli L, Bisagni G, Bria E. Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): focus on luminal cancers. Results from GIM13 - AMBRA study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
41
|
Patriarca C, Gervasoni C, d’Aiuto A, Roselli R, Petracco G, Laudati A, Cipolla M, Ronchi P, Giordano M. Plasticity of PD-L1 expression between nodal metastases and primary tumors in p16 negative squamous cell carcinoma of the oral cavity. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx430.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Mustacchi G, Cazzaniga M, Bria E, Bisagni G, Biganzoli L, Pronzato P, De Placido S, Romagnoli E, Montemurro F, Marchetti P, De Laurentiis M, Riccardi F, Turletti A, Michelotti A, Natoli C, Livi L, Del Mastro L, Donadio M, Garrone O, Giordano M. Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): From randomized trials to real-life setting: Results from GIM13 - AMBRA study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Cappuzzo F, Bidoli P, Chiari R, Chirco A, Turci D, Ardizzoni A, Santoro A, Natoli C, Francini G, Giordano M, Borra G, Defferrari C, Livi L, Berruti A, Minelli M, Ricevuto E, Illiano A, Puppo G, Delmonte A, Misino A. Real life experience with nivolumab in patients (pts) with advanced non-squamous NSCLC (nSq-NSCLC) exhibiting KRAS mutations: The Italian Expanded Access Program (EAP). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Cazzaniga M, Mustacchi G, Giordano M, Garrone O, Donadio M, del mastro L, Livi L, Natoli C, Michelotti A, Turletti A, Ferdinando R, De Laurentiis M, Marchetti P, Montemurro M, Romagnoli E, De Placido S, Pronzato P, Biganzoli L, Bisagni G, Bria E. Adherence to International ESO-ESMO (ABC) guide-lines in HER2-ve metastatic breast cancer (MBC) patients (pts): Preliminary results of the GIM 13 - AMBRA Study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
45
|
Di Gregorio E, Riberi E, Belligni EF, Biamino E, Spielmann M, Ala U, Calcia A, Bagnasco I, Carli D, Gai G, Giordano M, Guala A, Keller R, Mandrile G, Arduino C, Maffè A, Naretto VG, Sirchia F, Sorasio L, Ungari S, Zonta A, Zacchetti G, Talarico F, Pappi P, Cavalieri S, Giorgio E, Mancini C, Ferrero M, Brussino A, Savin E, Gandione M, Pelle A, Giachino DF, De Marchi M, Restagno G, Provero P, Cirillo Silengo M, Grosso E, Buxbaum JD, Pasini B, De Rubeis S, Brusco A, Ferrero GB. Copy number variants analysis in a cohort of isolated and syndromic developmental delay/intellectual disability reveals novel genomic disorders, position effects and candidate disease genes. Clin Genet 2017; 92:415-422. [PMID: 28295210 DOI: 10.1111/cge.13009] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2017] [Revised: 02/28/2017] [Accepted: 03/02/2017] [Indexed: 12/14/2022]
Abstract
BACKGROUND Array-comparative genomic hybridization (array-CGH) is a widely used technique to detect copy number variants (CNVs) associated with developmental delay/intellectual disability (DD/ID). AIMS Identification of genomic disorders in DD/ID. MATERIALS AND METHODS We performed a comprehensive array-CGH investigation of 1,015 consecutive cases with DD/ID and combined literature mining, genetic evidence, evolutionary constraint scores, and functional information in order to assess the pathogenicity of the CNVs. RESULTS We identified non-benign CNVs in 29% of patients. Amongst the pathogenic variants (11%), detected with a yield consistent with the literature, we found rare genomic disorders and CNVs spanning known disease genes. We further identified and discussed 51 cases with likely pathogenic CNVs spanning novel candidate genes, including genes encoding synaptic components and/or proteins involved in corticogenesis. Additionally, we identified two deletions spanning potential Topological Associated Domain (TAD) boundaries probably affecting the regulatory landscape. DISCUSSION AND CONCLUSION We show how phenotypic and genetic analyses of array-CGH data allow unraveling complex cases, identifying rare disease genes, and revealing unexpected position effects.
Collapse
Affiliation(s)
- E Di Gregorio
- University of Torino, Department of Medical Sciences, Turin, Italy.,Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - E Riberi
- Department of Public Health and Pediatrics, University of Torino, Turin, Italy
| | - E F Belligni
- Department of Public Health and Pediatrics, University of Torino, Turin, Italy
| | - E Biamino
- Department of Public Health and Pediatrics, University of Torino, Turin, Italy
| | - M Spielmann
- Research Group Mundlos, Max Planck Institute for Molecular Genetics, Berlin, Germany
| | - U Ala
- Computational Biology Unit, Molecular Biotechnology Center (MBC), Turin, Italy.,Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy
| | - A Calcia
- University of Torino, Department of Medical Sciences, Turin, Italy
| | - I Bagnasco
- Neuropsichiatria Infantile, Martini Hospital, ASL TO1, Turin, Italy
| | - D Carli
- University of Torino, Department of Medical Sciences, Turin, Italy
| | - G Gai
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - M Giordano
- Department of Health Sciences, Laboratory of Genetics, University of Eastern Piedmont and Interdisciplinary Research Center of Autoimmune Diseases, Novara, Italy
| | - A Guala
- SOC Pediatria, Castelli Hospital, Verbania, Italy
| | - R Keller
- Mental Health Department, ASL TO2, Adult Autism Center, Turin, Italy
| | - G Mandrile
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy.,Medical Genetics, San Luigi Gonzaga University Hospital, Orbassano (TO), Italy
| | - C Arduino
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - A Maffè
- Molecular Biology and Genetics Unit, Santa Croce e Carle Hospital, Cuneo, Italy
| | - V G Naretto
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - F Sirchia
- Molecular Biology and Genetics Unit, Santa Croce e Carle Hospital, Cuneo, Italy
| | - L Sorasio
- Pediatrics, Santa Croce e Carle Hospital, Cuneo, Italy
| | - S Ungari
- Molecular Biology and Genetics Unit, Santa Croce e Carle Hospital, Cuneo, Italy
| | - A Zonta
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - G Zacchetti
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy.,Department of Health Sciences, Laboratory of Genetics, University of Eastern Piedmont and Interdisciplinary Research Center of Autoimmune Diseases, Novara, Italy
| | - F Talarico
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - P Pappi
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - S Cavalieri
- University of Torino, Department of Medical Sciences, Turin, Italy
| | - E Giorgio
- University of Torino, Department of Medical Sciences, Turin, Italy
| | - C Mancini
- University of Torino, Department of Medical Sciences, Turin, Italy
| | - M Ferrero
- University of Torino, Department of Medical Sciences, Turin, Italy
| | - A Brussino
- University of Torino, Department of Medical Sciences, Turin, Italy
| | - E Savin
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - M Gandione
- Department of Neuropsychiatry, University of Torino, Turin, Italy
| | - A Pelle
- Medical Genetics, San Luigi Gonzaga University Hospital, Orbassano (TO), Italy.,Department of Clinical and Biological Sciences, University of Torino, Turin, Italy
| | - D F Giachino
- Medical Genetics, San Luigi Gonzaga University Hospital, Orbassano (TO), Italy.,Department of Clinical and Biological Sciences, University of Torino, Turin, Italy
| | - M De Marchi
- Medical Genetics, San Luigi Gonzaga University Hospital, Orbassano (TO), Italy.,Department of Clinical and Biological Sciences, University of Torino, Turin, Italy
| | - G Restagno
- Laboratory of Molecular Genetics, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - P Provero
- Computational Biology Unit, Molecular Biotechnology Center (MBC), Turin, Italy.,Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy
| | - M Cirillo Silengo
- Department of Public Health and Pediatrics, University of Torino, Turin, Italy
| | - E Grosso
- Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - J D Buxbaum
- Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York.,Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.,Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - B Pasini
- Molecular Biology and Genetics Unit, Santa Croce e Carle Hospital, Cuneo, Italy
| | - S De Rubeis
- Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York
| | - A Brusco
- University of Torino, Department of Medical Sciences, Turin, Italy.,Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy
| | - G B Ferrero
- Department of Public Health and Pediatrics, University of Torino, Turin, Italy
| |
Collapse
|
46
|
Giordano M, Takashima H, Poltorak M, Geller HM, Freed WJ. Constitutive Expression of Glutamic Acid Decarboxylase (GAD) by Striatal Cell Lines Immortalized using the tsA58 Allele of the SV40 Large T Antigen. Cell Transplant 2017; 5:563-75. [PMID: 8889215 DOI: 10.1177/096368979600500506] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Rodent striatal cells were immortalized using the A58 temperature-sensitive allele of the SV40 large T antigen. Seventy-eight clones and 10 mixed cultures were characterized at the nonpermissive and permissive temperatures. Based on morphology and expression of proteins, cells were classified into three primary types, with types b and c expressing some neuronal characteristics. Type a cells have an epithelial-like morphology with coarse cytoplasmic extensions and occasional fine processes. These cells express vimentin, do not grow well under serum-free conditions and, when confluent, form a uniform monolayer. Type b cells have a polygonal shape and usually extend multiple thin processes. These cells possess large nuclei with multiple nucleoli and do not express vimentin. Type c cells have a fibroblast-like appearance, are unipolar or multipolar, and their soma is smaller than that of type b cells. Type c cells do not express vimentin, and when confluent form a uniform monolayer. Some type b and c clones express NCAM and MAP-2. Several type b and c cell lines were found to consistently express glutamic acid decarboxylase (GAD) immunoreactivity under several tissue culture conditions. Selected cell lines were transplanted into the intact adult rat brain in several locations. Cells survived well for 15 wk and did not form tumors. The proteins expressed in vivo were similar to those expressed in vitro.
Collapse
Affiliation(s)
- M Giordano
- Section on Preclinical Neuroscience, NIMH Neuroscience Center at St. Elizabeths, Washington, DC 20032, USA
| | | | | | | | | |
Collapse
|
47
|
Dello Iacono S, Martone A, Pastore A, Filippone G, Acierno D, Zarrelli M, Giordano M, Amendola E. Thermally activated multiple self-healing diels-alder epoxy system. POLYM ENG SCI 2017. [DOI: 10.1002/pen.24570] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Affiliation(s)
- S. Dello Iacono
- CNR-IPCB Institute for Polymers Composites and Biomaterials; National Research Council; P.le E. Fermi 1 Portici Naples 80055 Italy
| | - A. Martone
- CNR-IPCB Institute for Polymers Composites and Biomaterials; National Research Council; P.le E. Fermi 1 Portici Naples 80055 Italy
| | - A. Pastore
- CNR-IPCB Institute for Polymers Composites and Biomaterials; National Research Council; P.le E. Fermi 1 Portici Naples 80055 Italy
| | - G. Filippone
- University of Naples “Federico II,” DICMAPI; P.le V. Tecchio, 80 1 Naples 80125 Italy
| | - D. Acierno
- University of Naples “Federico II,” DICMAPI; P.le V. Tecchio, 80 1 Naples 80125 Italy
| | - M. Zarrelli
- CNR-IPCB Institute for Polymers Composites and Biomaterials; National Research Council; P.le E. Fermi 1 Portici Naples 80055 Italy
| | - M. Giordano
- CNR-IPCB Institute for Polymers Composites and Biomaterials; National Research Council; P.le E. Fermi 1 Portici Naples 80055 Italy
| | - E. Amendola
- CNR-IPCB Institute for Polymers Composites and Biomaterials; National Research Council; P.le E. Fermi 1 Portici Naples 80055 Italy
| |
Collapse
|
48
|
Gigante M, Diella S, Santangelo L, Trevisson E, Acosta M, Amatruda M, Finzi G, Caridi G, Murer L, Accetturo M, Ranieri E, Ghiggeri G, Giordano M, Grandaliano G, Salviati L, Gesualdo L. Further phenotypic heterogeneity of CoQ10 deficiency associated with steroid resistant nephrotic syndrome and novel COQ2
and COQ6
variants. Clin Genet 2017; 92:224-226. [DOI: 10.1111/cge.12960] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2016] [Revised: 12/20/2016] [Accepted: 12/22/2016] [Indexed: 11/28/2022]
Affiliation(s)
- M. Gigante
- Department of Medical and Surgical Sciences; University of Foggia; Foggia Italy
| | - S. Diella
- Department of Medical and Surgical Sciences; University of Foggia; Foggia Italy
| | - L. Santangelo
- Department of Medical and Surgical Sciences; University of Foggia; Foggia Italy
- Unit of Pediatric Nephrology; University Hospital “Policlinico Consorziale - Giovanni XXIII”; Bari Italy
| | - E. Trevisson
- Clinical Genetics Unit, Department of Pediatrics; University of Padua and IRP “Città della Speranza”; Padua Italy
| | - M.J. Acosta
- Clinical Genetics Unit, Department of Pediatrics; University of Padua and IRP “Città della Speranza”; Padua Italy
| | - M. Amatruda
- Units of Nephrology and Pathology Anatomy; “Ospedale di Circolo e Fondazione Macchi”; Varese Italy
| | - G. Finzi
- Units of Nephrology and Pathology Anatomy; “Ospedale di Circolo e Fondazione Macchi”; Varese Italy
| | - G. Caridi
- Division of Nephrology; Laboratory on Pathophysiology of Uremia, G. Gaslini Institute; Genoa Italy
| | - L. Murer
- Division of Nephrology, Dialysis and Transplantation, Department of Pediatrics; Azienda Ospedaliera-University of Padua; Padua Italy
| | - M. Accetturo
- Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation; University “Aldo Moro”; Bari Italy
| | - E. Ranieri
- Department of Medical and Surgical Sciences; University of Foggia; Foggia Italy
| | - G.M. Ghiggeri
- Division of Nephrology; Laboratory on Pathophysiology of Uremia, G. Gaslini Institute; Genoa Italy
| | - M. Giordano
- Unit of Pediatric Nephrology; University Hospital “Policlinico Consorziale - Giovanni XXIII”; Bari Italy
| | - G. Grandaliano
- Department of Medical and Surgical Sciences; University of Foggia; Foggia Italy
| | - L. Salviati
- Clinical Genetics Unit, Department of Pediatrics; University of Padua and IRP “Città della Speranza”; Padua Italy
| | - L. Gesualdo
- Nephrology, Dialysis and Transplantation Unit, Department of Emergency and Organ Transplantation; University “Aldo Moro”; Bari Italy
| |
Collapse
|
49
|
Mustacchi G, Cazzaniga ME, Biganzoli L, De Laurentiis M, Del Mastro L, De Placido S, Donadio M, Garrone O, Giordano M, Latini L, Livi L, Marchetti P, Michelotti A, Montemurro F, Natoli C, Pronzato P, Riccardi F, Turletti A. Abstract P5-15-07: First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational “GIM-13 – AMBRA” Italian study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-15-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Frequency of CHT regimens according to biological subtypes and Setting of treatmentLuminal TumoursSettingRegimenAdj (%)1st-line (%)2nd-line (%)3rd-line (%)anthra-based (w/o Taxanes)44.27.15.19.9Anthra-Taxanes30.52.60.50CMF-like17.50.61.02.1Taxane mono/combo*6.319.314.521.5Pacliataxel + Bevacizumab020.24.33.7Platinum-based03.61.70.8Capecitabine +/- Vinorelbine019.122.217.4Eribuline002.312.4 TNBCSettingRegimenAdj (%)1st-line (%)2nd-line (%)3rd-line (%)Anthra-based (w/o Taxanes)25.73.15.116.2Anthra-Taxanes36.11.100CMF-like8.22.15.10Taxane mono/combo*6.318.417.810.8Paclitaxel + Bevacizumab024.71.70Platinum-based020.622.42.7Capecitabine +/- Vinorelbine025.720.610.8Eribuline003.429.7**Irrespectively of biological subtype, nab-paclitaxel was used in 3.6%, 15.3% and 16.4% of cases in 1st, 2nd and 3rd line, respectively
BACKGROUND
Breast Cancer prognosis improved in the last years due both to early diagnosis and Adj treatments. The choice of CHT regimens should consider previous Adj treatments, pattern of relapse and biological subtype. There are few information on the treatment of MBC in the clinical practice outside controlled trials, last study has been published 15 yrs ago in Italy.
PATIENTS AND METHODS
The GIM13-AMBRA Study is a multicenter longitudinal cohort study, describing the choice of first and subsequent lines of treatment for MBC in HER2-ve pts. We are collecting data of 30 consecutive pts from 42 Italian Centres who developed the first relapse in the years 2012-2015 and were treated with CHT, (+/- previous endocrine treatments (HT)) for MBC. One of the secondary aims is to evaluate the Time to Treatment Change (TTC) (time between treatment start and its change for any reason) as surrogate endpoint for Time To Progression outside clinical trials. The present report is focused on the choice of treatments in any line and TTC, according to biological subtypes. .
RESULTS
For the present analysis, 683 pts are evaluable. Pts with Luminal A and B tumours received CHT and HT in 65.3% (Adjuvant), 21.7% (1st line), 7.1% (2nd line) and 7% (3rd line) of the cases. The most used regimens according to tumour subtype and line of treatment are shown in Table 1.
Median TTC from 1st to 2nd line was 8.1 and 17.9 months in TNBC and Luminal tumours, respectively, whereas TTC from 2nd to 3rd line was 3.1 and 12.9 months, respectively.
CONCLUSION
Preliminary results of the AMBRA-GIM13 Italian observational study confirm that in most cases treatment for MBC is strongly related to the type of the Adj regimen, being the use of anthracyclines marginal in MBC, whereas taxanes are widely used in any line. In 1st line the most used regimens are Taxane and Bevacizumab or Capecitabine/Vinorelbine combinations. The last one remains the most used CHT in 2nd and 3rd lines. No difference have been observed according to biological subtype, except for Platinum-based regimens in TNBC. HT alone remains the preferred choice in 1st and 2nd line in Luminal cases. TTC seems to be a reliable surrogate for PFS in the “real world” practice . CHT still plays a crucial role in the treatment of MBC HER2-ve pts.
Citation Format: Mustacchi G, Cazzaniga ME, Biganzoli L, De Laurentiis M, Del Mastro L, De Placido S, Donadio M, Garrone O, Giordano M, Latini L, Livi L, Marchetti P, Michelotti A, Montemurro F, Natoli C, Pronzato P, Riccardi F, Turletti A. First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational “GIM-13 – AMBRA” Italian study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-15-07.
Collapse
Affiliation(s)
- G Mustacchi
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - ME Cazzaniga
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - L Biganzoli
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - M De Laurentiis
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - L Del Mastro
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - S De Placido
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - M Donadio
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - O Garrone
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - M Giordano
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - L Latini
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - L Livi
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - P Marchetti
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - A Michelotti
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - F Montemurro
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - C Natoli
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - P Pronzato
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - F Riccardi
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - A Turletti
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| |
Collapse
|
50
|
Cazzaniga ME, Mustacchi G, De Laurentiis M, Garrone O, Donadio M, Del Mastro L, Latini L, Livi L, Michelotti A, Montemurro F, Natoli C, Riccardi N, Turletti A, Giordano M, De Placido S, Biganzoli L, Pronzato P, Marchetti P. Abstract P5-14-09: Luminal A breast cancer: Is it really a “good prognosis” disease? Prelimary results of the GIM-13 - AMBRA study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-14-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was not presented at the symposium.
Collapse
Affiliation(s)
- ME Cazzaniga
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - G Mustacchi
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - M De Laurentiis
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - O Garrone
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - M Donadio
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - L Del Mastro
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - L Latini
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - L Livi
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - A Michelotti
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - F Montemurro
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - C Natoli
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - N Riccardi
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - A Turletti
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - M Giordano
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - S De Placido
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - L Biganzoli
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - P Pronzato
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - P Marchetti
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| |
Collapse
|